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A B S T R A C T
Background
In vitamin A deficient populations, the amount of vitamin A may be insufficient for maintenance of maternal health and levels in breast
milk may be insufficient for breastfeeding infants’ needs.
Objectives
To assess the effects of postpartum maternal vitamin A supplementation on maternal and infant health.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (31 July 2010), LILACS (1982 to July 2010), Web of
Science (1945 to July 2010) and Biological Abstracts (1998 to July 2010).
Selection criteria
Randomised controlled trials evaluating the effects of postpartum maternal vitamin A supplementation.
Data collection and analysis
Two review authors assessed the studies independently.
Main results
We included 12 trials at moderate risk of bias, enrolling 25,465 mother-baby pairs and comparing several postpartum doses (200,000-
400,000 IU) of vitamin A or 7.8 mg daily beta-carotene, with placebo, iron or no supplement; or higher (400,000 IU) versus lower
dose (200,000 IU). The majority of infants in all studies were at least partially breastfed for six months.
Maternal: we observed no impact of vitamin A on maternal mortality (two trials of 9,126 women), morbidity (one trial of 50 women)
or adverse effects (subset of 786 women in one trial). Vitamin A enhanced serum and breast milk retinol at three months in five trials,
but these improvements were generally not sustained.
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Infant: we observed no significant differences for infant mortality RR 1.14 95% CI 0.84 to 1.57 (five trials (6,170 infants) or morbidity
(three trials) except for fewer episodes of fever with vitamin A in one small trial. No significant differences in infant vitamin A status
were seen with maternal vitamin A supplementation (five trials).
No beneficial effects for maternal or infant health were associated with higher compared to lower doses of vitamin A in two trials.
Authors’ conclusions
The lack of effect on maternal and infant mortality and morbidity, with exception of some improved infant morbidity in one small
study, and the improvement in maternal vitamin A status, suggest that maternal postpartum vitamin A supplementation offers limited
benefits.
P L A I N L A N G U A G E S U M M A R Y
Vitamin A supplementation for breastfeeding mothers
While the amount of vitamin A in well-nourished mothers’ breast milk is sufficient to meet the needs of their infants, this may not
be the case for mothers from populations with vitamin A deficiency. Therefore, trials have tested whether giving mothers vitamin A
supplements as single doses soon after birth or beta-carotene for long periods can improve the health and survival of these mothers and
their babies. Ten of the 12 trials in this review compared a single dose of vitamin A and placebo, with one trial supplementing women
with beta-carotene for nine months after birth. Two studies compared a higher dose with a lower dose of vitamin A. None of the trials
was able to show an effect on infant death and only one small study showed improved infant health. None of the trials was able to
show an effect on maternal death or morbidity. A significant improvement was seen for maternal serum retinol, breast milk retinol and
vitamin A liver stores after single dose of vitamin A supplementation. Vitamin A did not show any adverse effects in these trials, but
this may not apply for women and babies from well nourished populations.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin A supplementation compared to placebo for postpartum mothers
Patient or population: postpartum mothers
Settings:
Intervention: Vitamin A supplementation
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
placebo Vitamin A supplementa-
tion
Maternal mortality
Follow-up: mean 12
months
3 per 10001 3 per 1000
(2 to 5)2
HR 1.11
(0.81 to 1.51)
8577
(1 study)
⊕⊕©©
low3,4,5,6,7
Maternal morbidity: In-
fections (total days of ill-
ness per days of follow-
up)
Follow-up: mean 3
months
See comment See comment 50
(1 study)
⊕©©©
very low8,9,10,11,12
30/2281 with vitamin
A versus 28/2281 with
placebo; no statistical
comparison performed13
Maternal adverse ef-
fects after administra-
tion: vomiting
8 per 1000 3 per 1000
(0 to 25)
RR 0.33
(0.03 to 3.14)
786
(1 study)
⊕⊕©©
low4,7,14
Maternal serum retinol
(mcmol/L)
mcmol/L
Follow-up: 3-3.5 months
Themeanmaternal serum
retinol (mcmol/l) in the
control groups was
1.28 mcmol/L
ThemeanMaternal serum
retinol (mcmol/L) in the
intervention groups was
0.17 higher
(0.06 to 0.28 higher)
258
(3 studies)
⊕⊕©©
low15
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Maternal low hepatic vi-
tamin A stores (MRDR
greater than or equal to
0.06)
Follow-up: 3 months
543 per 1000 179 per 1000
(81 to 386)
RR 0.33
(0.15 to 0.71)
69
(1 study)
⊕⊕⊕©
moderate16,17,18
Maternal low hepatic vi-
tamin A stores (RDR >
20%)
Follow-up: 3 months
87 per 1000 100 per 1000
(36 to 283)
RR 1.15
(0.41 to 3.25)
139
(1 study)
⊕⊕⊕©
moderate19,20,21
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 ZVITAMBO Study Group: The data for the number of deaths in the placebo group have been estimated from the original reference. The
study did not report the number of deaths in the placebo group; we have estimated the figure using the reported number of participants
in the placebo group, the total number of participants in both groups, the total number of deaths in both groups, and the hazard ratio
of 1.11.
2 ZVITAMBO Study Group: The data for the number of deaths in the intervention group have been estimated from the original reference.
The study did not report the number of deaths in the vitamin A group; we have estimated the figure using the reported number of
participants in the vitamin A group, the total number of participants in both groups, the total number of deaths in both groups, and the
hazard ratio of 1.11.
3 ZVITAMBO Study Group: The analysis was not by ITT, but the attrition rate was low (11%), and therefore a point has not been deducted
for limitations in design
4 ZVITAMBO Study Group: One study only, therefore no inconsistency.
5 ZVITAMBO Study Group: Estimated rather than actual figures of mortality.
6 ZVITAMBO Study Group: Wide 95% confidence intervals that cross the line of no effect, which therefore does not exclude benefit or
harm of vitamin A.
7 ZVITAMBO Study Group: Few events in trial.
8 Roy 1997: Unclear allocation concealment and unblinded control group (no placebo).
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9 Roy 1997: No statistical analysis for comparison of vitamin A versus placebo.
10 Roy 1997: One study only, therefore no inconsistency.
11 Roy 1997: Maternal fever a proxy outcome for infectious morbidity.
12 Roy 1997: Few events in trial.
13 Roy 1997: Number of cumulative days of illness (numerator) and number of people days’ follow-up (denominator). The number of
people days has been extracted from the original reference.
14 ZVITAMBO Study Group: Unclear why only 766 women out of the 14,110 women randomised were included in the assessment of
adverse effects.
15 RETIBETA, Roy 1997, Stoltzfus 1993a: Reasons for attrition were not reported, and no ITT analyses were performed, in RETIBETA
and Stoltzfus 1993a. Unclear allocation concealment and unblinded control group (no placebo) in Roy 1997.
16 RETIBETA: Reasons for attrition were not reported, and no ITT analysis was performed; however, follow-up rates were greater than
90%, and therefore no point has been deducted.
17 RETIBETA: One study only, therefore no inconsistency.
18 RETIBETA: Few events in trial.
19 Stoltzfus 1993a: Reasons for attrition were not reported, and no ITT analysis was performed; however, follow-up rates were 89% at 6
months, and therefore no point has been deducted.
20 Stoltzfus 1993a: One study only, therefore no inconsistency.
21 Stoltzfus 1993a: Wide 95% confidence intervals that cross the line of no effect, which therefore does not exclude benefit or harm of
vitamin A.
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B A C K G R O U N D
Description of the condition
Importance of vitamin A
Vitamin A is a generic term for a group of fat-soluble substances
that carry out similar biological activity in human metabolism. It
plays an important role in normal vision, gene expression, growth
and physical development, maintenance and proliferation of ep-
ithelial cells, and immune function, at all stages of life, particularly
duringpregnancy and lactation, givenmaternal, fetal and newborn
requirements (Butte 2002; FNB2000;WHO1996;WHO1998).
The dietary sources of pro-vitaminA (alfa- and beta-carotene, alfa-
cryptoxanthin) are vegetables such as carrot, pumpkin, papaya,
buriti, and red palm oil; and animal foods rich in pre-formed vita-
min A, such as dairy products (whole milk, yogurt, cheese), liver,
fish oils and humanmilk (FAO/WHO2001; FNB 2000). Inmost
cultures, young infants depend on breast milk to obtain adequate
amounts of vitamin A (WHO 1998), which is highly dependent
upon maternal diet and nutritional status. In well-nourished pop-
ulations the breast milk amounts of vitamin A are adequate to
meet the infants’ requirements during the first six months of life.
In populations deficient in vitamin A, the amount in breast milk
will be suboptimal and insufficient to build or maintain stores of
this micronutrient in nursing infants (Butte 2002; WHO 1998).
Biological Indicators
Specific biological indicators of vitamin A deficiency (VAD) can
be divided into two types: clinical and subclinical. Among the clin-
ical indicators is xerophthalmia, which includes all ocular mani-
festations of VAD from night blindness to corneal ulceration, and
resultant blindness (Sommer 1993). Subclinical indicators can in-
clude measurement of serum retinol (less than 0.7 µmol/L), breast
milk retinol (less than 1.05 µmol/L or 0.28 µmol/g milk fat), rel-
ative dose response (RDR), and modified relative dose response
(MRDR) (WHO 1996). Although there is not consensus, serum
retinol less than 1.05 µmol/l has been proposed to reflect low
vitamin A status among pregnant and lactating women (WHO
2009,West 2002). RDRandMRDRare indirectmethods to assess
the level of vitamin A in the liver. Other non-specific symptoms,
such as increased maternal and infant morbidity and mortality,
increased risk of anaemia, slowed infant growth and development
can be related to VAD (FAO/WHO 2001, WHO 2009). RDR
andMRDR are indirect methods to assess the level of vitamin A in
the liver. Other non-specific symptoms, such as increased mater-
nal and infant morbidity and mortality, increased risk of anaemia,
slowed infant growth and development can be related to VAD
(FAO/WHO 2001).
Vitamin A and adverse effects
There are limited human data on the potential teratogenicity of
high doses of vitamin A in women exposed during early preg-
nancy. However, teratogenic effects from natural metabolites of
vitamin A (like trans retinoic acids and 13-cis retinoic acids) are
well documented from case studies of women exposed to high
doses of retinoic acid derivatives within the first six weeks of preg-
nancy. Extensive epidemiologic studies have produced no evidence
of teratogenicity in the human fetus after six weeks of pregnancy
(Rasmussen 1998). Maternal or infant supplementation with high
doses of vitamin A (more than 50,000 IU) can produce adverse
effects including nausea, headache, fever, vomiting, transient di-
arrhoea, increased cerebrospinal fluid pressure, blurred vision and
lack of muscular co-ordination (Allen 2002).
Vitamin A interaction with other micronutrients
It is believed that zinc status may influence vitamin Ametabolism,
including its absorption, transport and utilisation, probably
through regulation of vitamin A transport and oxidative conver-
sion of retinol to retinal. However, randomised trials have failed
to show a consistent effect of zinc supplementation on vitamin A
status (Christian 1998).
There is evidence that VAD impairs iron mobilisation from stores
and its transportation, resulting in anaemia (Lynch 1997). The
role of vitamin A in iron absorption is unconfirmed; according to
Garcia-Casal 1998, vitamin A forms a complex with iron, increas-
ing its absorption, but Walczyk 2003 found a slightly negative
effect of this vitamin.
Some studies have shown that iron deficiency may influence vita-
min A metabolism (Oliveira 2008a), decreasing liver mobilisation
and serum retinol concentration (Rosales 1999; Jang 2000; Strube
2002). Munoz 2000 conducted a clinical trial and found that iron
supplementation improved the indicators of vitamin A status in
preschoolers from Mexico.
Vitamin A deficiency around the world
The global distribution of VAD, presented by the World Health
Organization (WHO) (WHO 1995), classifies countries by the
significance of VAD as a public health problem, based on clin-
ical and subclinical (serum retinol) indicators. The most widely
affected areas are in Africa, Asia and Latin America. The recent
prevalence presented byWHO(WHO2009), includingdata from
1995 to 2005, indicates that Africa and South-East Asia have the
highest burden of VAD. Although these estimations were pro-
duced by different methodologies, there is some indication that
the prevalence of xerophthalmia among pre-school children de-
creased, but the subclinical VAD (serum retinol concentration) in
pre-school children and pregnant women increased, possibly due
to improved methods of assessing, and a wider population being
assessed (WHO 2009). Results relating to lactating women were
not considered in these publications. A study carried out in Nepal
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showed that 27% of postpartum women were vitamin A deficient
(West 1997). Another study in Bangladesh found that 13.3% of
lactating women presented with VAD (Ahmed 2003).
Vitamin A supplementation during pregnancy
A Cochrane systematic review (Van den Broek 2002) of five trials
with a total of 23,426 pregnant women, mostly from countries
with significant levels of VAD, noted a possible beneficial effect
on maternal mortality after weekly supplementation, a reduction
in maternal night-blindness and a reduction in maternal anaemia
in some, but not all studies.
Breastfeeding around the world
According to the WHO (WHO 2010), 36% of infants are ex-
clusively breast fed for the first six months of life. South-East
Asia presents the highest prevalence (48%) and Europe the lowest
(23%). The prevalence in Africa and America is the same (31%).
Considering income, the low and lower middle income groups
showed the highest proportion (around 38%). In Bangladesh, In-
dia, Indonesia and Nepal 43%, 46%, 32% and 53% of infants are
exclusively breast fed during the first six months. The prevalences
in Africa vary by the specific country. In Ghana the proportion is
63%, followed by Gambia (41%), Tanzania (41%), Kenya (32%),
and Zimbabwe (22%). In South America these differences are also
observed. For example, in Brazil the prevalence is 40% and in Peru
73%.
Maternal mortality around the world
In Africa and South-East Asia the maternal mortality ratios
(MMR) average 900/100,000 and450/100,000 live births, respec-
tively. Although these areas present the highest maternal mortality
around the world, the ratios are not homogenous when consid-
ering different countries within continents. The MMR is higher
in Nepal (830/100,000) than in Bangladesh (570/100,000), In-
dia (450/100,000) or Indonesia (420/100,000). The differences
among African countries are also evident. In Tanzania the MMR
is 950/100,000; followed by Zimbabwe (880/100,000); Gambia
(690/100,000); Ghana and Kenya (both 560/100,000 live births).
In North America and Europe, these ratios are below 100/100,000
live births, but the rates are relatively high in Brazil (110/100,000)
and Peru (240/100,000 live births) (WHO 2010).
Description of the intervention
Vitamin A supplementation for postpartum mothers
Vitamin A supplementation may take a number of forms: for
example, as Vitamin A, measured in international units (IU) of
Retinyl palmitate (3.33 IU or 0.003491 micromol of retinol = 1
microgram or 1 Retinol Equivalent (RE) (IVACG 2004), water
miscible formulation, or as beta-carotene. Synthetic beta-carotene
supplements result in improved breast milk vitamin A concen-
trations compared with dietary sources of beta-carotene (De Pee
1995).
WHO, UNICEF and the International Vitamin A Consultative
Group recommend that in areas of endemic VAD, high doses of
supplementary vitamin A should be given to breastfeeding women
during the postpartum period (to six weeks after childbirth), as a
strategy to improve mothers’ and infants’ stores of this micronu-
trient (Ross 2002; WHO 1996).
Four scenarios in which vitamin A supplements could be given in
VAD countries, considering safe dosage and frequency of admin-
istration, are: (1) maternal supplementation during pregnancy;
(2) supplementation for mothers in the first six months postpar-
tum; (3) supplementation of infants before six months of age; and
(4) supplementation of both the mothers during the safe infertile
postpartum period and infants under six months of age (WHO
1998).
At the population level, for mothers from VAD countries who are
not breastfeeding, a high dose of vitamin A (over 25,000 IU and
usually 200,000 IU) during the first four weeks after delivery could
be beneficial. Beyond six months, for these mothers no more than
10,000 IU daily should be given. Non-breast-fed infants (less than
six months of age) could receive a single high dose of 50,000 IU of
vitaminA or two doses of 25,000 IU approximately amonth apart,
to meet their needs if they are not receiving a fortified breast-milk
substitute. However, for mothers who are breastfeeding, a high
dose given up until 60 days postpartum could be beneficial for
them and as well as for their infants through higher concentration
of vitamin A in breast milk (WHO 1998).
According to WHO’s recommendations (WHO 1998), research
that considers the supplementation of mothers up to eight weeks
postpartum should include an evaluation of maternal outcomes,
such as morbidity, mortality, serum retinol and breast milk retinol
and its metabolites; long-term effects on morbidity, mortality and
vitamin A status in infancy up to three years of age; as well as
effects on partial weaning/cessation of breastfeeding onmorbidity,
mortality, vitamin A status and return to fertility.
Other integrated approaches to control VAD are the improvement
of dietary quality, quantity and food fortification (WHO 1998).
Why it is important to do this review
Numerous studies and programs have involved postpartum sup-
plementation that aims to improve women’s and infants’ health in
regions of vitamin A deficiency. However, there are no consistent
practices or recommendations. A systematic review of the relevant
randomised controlled trials is therefore warranted.
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O B J E C T I V E S
To assess the effects of vitamin A supplementation, alone or in
combination with other micronutrients (e.g. iron, folic acid, vi-
tamin E), in mothers during the postpartum period, on maternal
and infant health.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials evaluating the effects of vitamin
A supplementation in mothers during the postpartum period,
including cluster-randomised studies and excluding quasi-ran-
domised studies.
Types of participants
Mothers in the postpartum period, breastfeeding or not, from
vitamin A deficiency areas, without confirmed chronic diseases
(e.g. HIV). We included maternal data from studies conducted in
areas with high prevalence of HIV without individual diagnostics
at baseline. We considered only data of HIV-negative mothers in
studies conducted with both HIV-positive and -negative mothers.
Types of interventions
Maternal vitamin A supplementation (beta-carotene or retinyl
palmitate or water miscible formulation) alone or in combination
with other micronutrients (examples: iron, folic acid, vitamin E)
compared with placebo, no intervention, other micronutrient, or
a lower dose of vitamin A, commenced at any time during the
postpartum period, that is, within 24 hours of birthing until six
weeks after giving birth.
Studies included maternal administration of high doses (given as
a single dose of 200,000, 300,000, or 400,000 IU) or two doses
(for a total of 400,000 IU), daily (7.8 mg or 4,327 IU) doses or a
combination of high or lower doses.
Studies that involved continuous daily/weekly supplementation
for mothers during reproductive age (pre-pregnancy or during
pregnancy) are addressed in a separate systematic review (Van den
Broek 2002).
Several studies included infant supplementation, in addition to
maternal postpartum supplementation. We considered maternal
outcomes from these studies. We included infant outcomes only
when they had been measured prior to commencement of infant
supplementation.
Types of outcome measures
When studies involved bothmaternal and infant supplementation,
we reviewed them for maternal outcomes and limited the infant
outcomes to those measured prior to commencement of infant
supplementation. In this way, we only included results related
to a comparison of maternal supplementation or no treatment/
placebo; or different maternal supplementation regimens. With
the exception of adverse effects of vitamin supplementation, we
reviewed outcomes for up to 12 months postpartum.
Primary outcomes
Primary maternal outcomes
1. Mortality;
2. morbidity (febrile illness, respiratory tract infection,
diarrhoea);
3. adverse effects of vitamin A within three days after receiving
supplement.
Primary infant outcomes
1. Mortality;
2. morbidity episodes (febrile illness, respiratory tract
infection, diarrhoea, and others);
3. adverse effects of vitamin A supplementation within three
days after receiving supplement.
Secondary outcomes
Secondary maternal outcomes
1. Serum retinol concentration;
2. vitamin A hepatic stores (MRDR or RDR);
3. breast milk retinol concentration;
4. vitamin A deficiency (clinical: impaired visual adaptation to
darkness, night blindness, xerophthalmia; and subclinical:
abnormal conjunctival impression cytology);
5. anaemia.
Secondary infant outcomes
1. Serum retinol concentration;
2. vitamin A hepatic stores (RDR or MRDR);
3. clinical vitamin A deficiency.
Search methods for identification of studies
Electronic searches
8Vitamin A supplementation for postpartum women (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (31
July 2010).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, we searched LILACS - Latin American and Caribbean
Health Sciences by Bireme (1982 to July 2010), Web of Science
(1945 to July 2010), Biological Abstracts (1998 to July 2010)
using the search strategies detailed in Appendix 1.
We also searchedHumanNutrition (1982 toOctober 2007), Food
Sciences & Tech Abstracts (1969 to November 2008), Food and
Human Nutrition (1975 to October 2007), and AGRIS (1975 to
October 2007). See Appendix 1 for details.
We did not apply any language restrictions.
Data collection and analysis
Selection of studies
At least two review authors (JM Oliveira-Menegozzo, DP Berga-
maschi, CE East, P Middleton) assessed potentially eligible trials
identified by the literature search to determine if they met the
inclusion criteria for the review. We made decisions regarding in-
clusion independently and compared results. We resolved any dis-
agreement through discussion.
Data extraction and management
For eligible studies, at least two authors (JM Oliveira-Menegozzo,
CE East, P Middleton) independently extracted data and com-
pared the results. We resolved discrepancies through discussion.
We double-checked data against printouts of data entered into
Review Manager software (RevMan 2008).
We carried out the meta-analysis using the Review Manager soft-
ware (RevMan 2008).
Assessment of risk of bias in included studies
At least two authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2009). We resolved
any disagreements by discussion.
(1) Sequence generation (checking for possible selection
bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• adequate (any truly random process, e.g. random number
table; computer random number generator),
• inadequate (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number) or,
• unclear.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence and determine whether intervention allo-
cation could have been foreseen in advance of, or during recruit-
ment, or changed after assignment.
We assessed the methods as:
• adequate (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear.
(3) Blinding (checking for possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received.We considered that studies are
at low risk of bias if they were blinded, or if we judged that the
lack of blinding could not have affected the results. We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• adequate, inadequate or unclear for participants;
• adequate, inadequate or unclear for personnel;
• adequate, inadequate or unclear for outcome assessors.
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(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we would have re-included missing data in
the analyses which we undertook. However, this did not apply to
any of the included studies. We did not specify a level of missing
data to assess that a study was adequate. We assessed methods as:
• adequate;
• inadequate;
• unclear.
(5) Selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• adequate (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review had been reported);
• inadequate (where not all the study’s pre-specified outcomes
had been reported; one or more reported primary outcomes were
not pre-specified; outcomes of interest were reported
incompletely and so cannot be used; study failed to include
results of a key outcome that would have been expected to have
been reported);
• unclear.
(6) Other sources of bias
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• yes;
• no;
• unclear.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2009). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it was likely to impact on the findings. We planned
to explore the impact of the level of bias through undertaking
sensitivity analyses - see ’Sensitivity analysis’.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
(RR) with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes
were measured in the same way between trials.
Where data were reported in a format that did not allow for entry
into the RevMan software, we have reported the published results
in tables or in text.
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses
alongwith individually randomised trials. If we had identified clus-
ter trials, we planned to adjust their sample sizes using the meth-
ods described in the Handbook (Secion 16.3.4) using an estimate
of the intracluster correlation co-efficient (ICC) derived from the
trial (if possible), from a similar trial or from a study of a similar
population.
If cluster studies are in included in future review updates, we will
use ICCs from other sources; we will report this and conduct sen-
sitivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensi-
tivity analysis if we identified such studies.
Although not ultimately required for the included studies, for all
outcomes, we planned to carry out analyses, as far as possible, on
an intention-to-treat basis, i.e. we planned to attempt to include
all participants randomised to each group in the analyses, and
all participants would have been analysed in the group to which
they were allocated, regardless of whether or not they received the
allocated intervention. If studies requiring this are identified in
future review updates, the denominator for each outcome in each
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trial will be the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if T² was greater than zero and either I² was greater than
30% or there was a low P-value (less than 0.10) in the Chi² test
for heterogeneity.
Assessment of reporting biases
If 10 or more studies were meta-analysed we would have investi-
gated reporting biases (such as publication bias) using funnel plots.
However, no outcomes had results from 10 or more studies. If this
becomes necessary in future review updates, we will assess funnel
plot asymmetry visually, and use formal tests for funnel plot asym-
metry. For continuous outcomes we will use the test proposed by
Egger 1997, and for dichotomous outcomes we will use the test
proposed by Harbord 2006. If we detect asymmetry in any of
these tests or by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
Wecarried out statistical analysis usingRevMan software (RevMan
2008).We use fixed-effectmeta-analysis for combining data where
it was reasonable to assume that studies were estimating the same
underlying treatment effect: i.e. where trials were examining the
same intervention, and the trials’ populations and methods were
judged sufficiently similar. If there was clinical heterogeneity suf-
ficient to expect that the underlying treatment effects differed be-
tween trials, or if substantial statistical heterogeneity was detected,
we used random-effects meta-analysis to produce an overall sum-
mary if an average treatment effect across trials was considered
clinically meaningful. We treated the random-effects summary as
the average range of possible treatment effects and we discussed
the clinical implications of treatment effects differing between tri-
als. If the average treatment effect was not clinically meaningful,
we did not combine trials.
If we used random-effects analyses, we presented the results as the
average treatment effect with its 95% confidence interval, and the
estimates of T² and I2.
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated it using
subgroup analyses. We considered whether an overall summary
was meaningful, and it was, we used random-effects analysis to
produce it.
We planned to conduct the following sub-groups analyses of pri-
mary outcomes, if sufficient data were available:
1. type of supplement (vitamin A (retinyl palmitate or water
miscible formulation) or beta-carotene);
2. duration of supplementation (daily, single or double dose);
3. dose of supplement (200,000-300,000 IU or 400,000 IU);
4. type of control group (supplementation versus placebo/no
supplement, or higher versus lower supplementation dose);
5. duration of breastfeeding.
Sensitivity analysis
If we identified substantial heterogeneity, we investigated it using
sensitivity analyses.
R E S U L T S
Description of studies
Included studies
We included 12 studies enrolling 25,465 mother-baby pairs re-
siding in low-income settings in India, Bangladesh, Indonesia,
Tanzania, Gambia, Zimbabwe, Kenya, Ghana and Peru, coun-
tries in which women in the studies were likely to have low vi-
tamin A levels and low nutritional status. The ’Characteristics of
included studies’ table provides further information on these trials.
Although all studies reported or implied that postpartum women
breastfed their infants, the available details made it impractical to
perform subgroup analysis by duration of breastfeeding. More-
over, there were insufficient data to perform sensitivity analyses.
Dosage and duration of vitamin A supplementation
Nine studies (Ayah 2007; Bhaskaram 2000; Newton 2005;
Roy 1997; Stoltzfus 1993a; Venkatarao 1996; Vinutha 2000;
WHO/CHD IVASSG; ZVITAMBO Study Group) administered
a single dose of vitamin A in the form of retinyl palmitate or
water miscible formulation (200,000; 300,000 or 400,000 IU)
supplementation for mothers within the first days or weeks post-
partum. Eight of the trials compared vitamin A supplementation
with placebo (Ayah 2007; Bhaskaram 2000; RETIBETA Project;
Stoltzfus 1993a; Venkatarao 1996; ZVITAMBO Study Group;
WHO/CHD IVASSG; Newton 2005). In two studies, women
in the control group received no intervention (Vinutha 2000) or
were given iron supplementation (as were those in that study’s
intervention group) (Roy 1997). The RETIBETA Project used a
three-group approach of single postpartum dose of vitamin A (as
retinyl palmitate) followed by placebo for nine months, placebo
at enrolment followed by daily beta-carotene supplementation for
nine months, or placebo at enrolment and daily for nine months.
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Two trials compared a lower dose of vitamin A (200,000 IU) with
a higher dose (400,000 IU) (Darboe 2007; Idindili 2007).
The studies reported the dosage in a variety of units: for the pur-
pose of this review, dosages have generally been presented as in-
ternational units (IU), based on the calculation of 3.33 IU or
0.003491 micromol of retinol = 1 microgram or 1 Retinol Equiv-
alent (RE).
Breastfeeding patterns
Eight of the included studies reported that women breastfed
their infants, with several studies noting that infants were exclu-
sively breastfed (Vinutha 2000 for the duration of the study and
Idindili 2007 for the firstmonth) andothers indicating that infants
were at least partially breast fed to six months (Bhaskaram 2000;
RETIBETA Project; Roy 1997; Venkatarao 1996; WHO/CHD
IVASSG; ZVITAMBO Study Group). All four studies that did
not specify details of breastfeeding provided strong surrogate ev-
idence to support the likelihood of at least partial breastfeeding.
The studies by Ayah 2007 and Darboe 2007 reported breast milk
retinol levels at six months postpartum, whilst the study title,
background and/or discussion material suggested that the reports
from Newton 2005 and Stoltzfus 1993a related to breastfeeding,
although the duration or extent cannot be estimated.
Excluded studies
We excluded four trials because they used alternate, rather than
randomised allocation (Ala-Houhala 1988; Basu 2003, Bezerra
2010; Tchum 2006). We excluded eight trials that involved pro-
vision of vitamin A rich foods, rather than vitamin A supple-
mentation (Canfield 2001; De Pee 1995; Filteau 1999; Gossage
2000; Khan 2007; Lietz 2001; Lietz 2006; Ncube 2001). We
also excluded two studies involving long-term supplementation
for women of reproductive age (NNIPS-2; ObaapaVitA). (See
’Characteristics of excluded studies’).
Risk of bias in included studies
We assessed the overall risk of bias in the 12 included trials as being
moderate (Figure 1; Figure 2)
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
In theWHOCHD Immunization Linked Vitamin A supplemen-
tation multi-centre trial (WHO/CHD IVASSG), mother and in-
fant pairs were individually randomised to one of four treatment
groups. Randomisation was carried out by identification numbers
generated by computer and assigned as random permuted blocks
of size eight. The codes were kept by WHO in Geneva.
Participants in the RETIBETA Project were individually ran-
domised. Before beginning the study, treatment codes and follow-
up schedules were assigned to a sequence of identification numbers
in blocks of 18 using a random number table. During enrolment,
the women were randomly allocated to one of three treatment
groups and to a follow-up schedule.
In the Ayah 2007 trial, two random sequences were prepared for
mothers and infants. The randomisation code was concealed for
the entire trial duration and only revealed after completion of data
analysis. In the ZVITAMBO trial (ZVITAMBO Study Group)
randomisation was done by computer generation of identification
numbers in blocks of 12.
Subjects from theGambia trial (Darboe 2007)were randomised by
a senior scientist, who then packed and labelled the supplements,
by blocks (16 per block) to allow for possible effects of season
of birth. In the Idindili 2007 trial, individual randomisation was
achieved by using a list of study numbers that had been randomly
assigned to an intervention arm in blocks of ten, generated by the
Data and SafetyMonitoring Board. The Stoltzfus 1993a trial used
individual randomisation to treatment codes in blocks of eight.
The reports from the trials by Venkatarao 1996, Roy 1997,
Bhaskaram 2000 and Vinutha 2000 provided no information
about the method of randomisation and concealment.
Blinding
For most studies, the vitamin A and placebo capsules were iden-
tical in appearance (see Risk of bias tables in Characteristics of
included studies. In one study (RETIBETA Project) the capsules
differed slightly in colour, but they were individually wrapped in
foil, making the direct comparisons between groups unlikely.
In the study by Idindili 2007, there was not enough detail to
judge whether participants were blinded, while the Vinutha 2000
study did not provide detail on blinding. Stoltzfus 1993a noted
that all investigators, field, and laboratory staff were blinded to the
randomisation code until field work was completed.
Incomplete outcome data
In the Venkatarao 1996 trial study there was a 24.2% overall loss
of follow-up, distributed similarly between the three groups and
attributed to post-randomisation exclusions for medical reasons
such as congenital abnormalities or jaundice, migration and mis-
cellaneous. In the study by Roy et al (Roy 1997) no losses to fol-
low-up were discussed, but data from the tables indicate 100% of
follow-up. In the Vinutha et al (Vinutha 2000) clinical trial the
loss of follow-up rate was 22.9%. In the trial by Bhaskaram et al
(Bhaskaram 2000) the rates of loss to follow-up were 13% and
54% until three and six months postpartum, respectively. Ayah
2007 reported a 12.6% loss to follow-up by 14 weeks’ postpartum
and a 22.9% loss by six months. In the trial fromGambia (Darboe
2007) 89.5% of mothers and infants were followed up until 12
months. Idindili 2007 reported 19%, 20.5%, 22.8% of loss by
three, six, and nine months, respectively. Attrition was 11.3% (in
both the vitamin A and placebo groups) for HIV-negative women
(985/9562) in the report from the ZVITAMBO Study Group.
Twenty-three of the total 220 women in the RETIBETA Project
missed one or more visits, resulting in follow-up rates of 98%,
95%, and 92% at three, six, and nine months postpartum, respec-
tively, with data reported for these participants in most outcomes.
The exception was for maternal hepatic stores of vitamin A and
serum retinol concentrations, for which approximately 50% of
women were sampled: the report does not specify why all women
were not tested. The study by Stoltzfus 1993a had a 9% loss to
follow-up in each group by three months and 13% and 5% losses
in the vitamin A and control groups respectively by six months.
Loss of follow-up at nine months for the WHO/CHD IVASSG
study was 783 (17%) in the intervention group and 770 (16%)
in the placebo group. This increased to 25% and 24.5% in the
intervention and control groups respectively by 12 months. Infant
death was the only outcome of interest for this review at this time,
therefore it was recorded in this review for the nine month follow-
up time, rather than at 12 months. Biochemical markers had been
measured in a subgroup of approximately 100 mothers and their
infants from each of the three participating countries: the exact
number sampled increased from the first to the second timeframe,
which meant we were unable to determine loss to follow up from
the report.
Selective reporting
We judged all but one trial to be at risk of selective reporting; for
example only five of the 12 trials reported infant mortality and
only two reported maternal mortality.
Other potential sources of bias
We judged most trials as unclear for risk of other bias, mostly due
to a lack of clarity about any influence of funding bodies.
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Effects of interventions
See: Summary of findings for the main comparison Vitamin A
supplementation compared to placebo for postpartum mothers
Primary maternal outcomes
Maternal mortality
Two studies evaluated maternal mortality for a total of 9126
women (Ayah 2007; ZVITAMBO Study Group). The study by
Ayah 2007 reported no statistically significant difference in ma-
ternal mortality to six months (n = 564, RR 0.50, 95% CI 0.09
to 2.71) - Analysis 1.1. There were no reported differences in ma-
ternal deaths following vitamin A supplementation or placebo in
HIV-negative women (n = 8562) followed to six months (Hazard
Ratio (HR) 1.40, 95% CI 0.4, 5.0) or 12 months (HR 1.11, 95%
CI 0.81, 1.51) in the report by Zvandasara (ZVITAMBO Study
Group): we report here the adjusted HR and confidence intervals
for maternal mortality, as there was insufficient detail to re-analyse
using RevMan software (RevMan 2008).
Maternal morbidity
One small study of 50 women (Roy 1997) reported no significant
difference in cumulative episodes of diarrhoea, respiratory infec-
tion or fever - Analysis 1.2, Analysis 1.3, Analysis 1.4).
Adverse effects of vitamin A supplementation
In a subset of 788 mother-infant pairs in the ZVITAMBO Study
Group, no statistically significant differences were seen in adverse
effects within 30 hours of supplementation, including headache,
blurred vision, drowsiness, vomiting, poor appetite or abdominal
pain following a single dose of 400,000 IU vitamin A or placebo
- Analysis 1.5.
Secondary maternal outcomes
Maternal serum retinol
Six studies reported maternal serum retinol values, measured be-
tween six weeks and nine months after birth, for a total of 1418
women (Analysis 1.6; Analysis 1.7; Analysis 1.8; Analysis 1.9).
Few analyses included meta-analysis of more than three of these
studies at a time, due to the clinical and statistical heterogeneity
of reported data.
Maternal serum retinol concentrations were not enhanced by the
largest single dose (400,000 IU), when measured at one and a half
months (260 HIV-negative women, mean difference (MD) 0.09
µmol/L, 95% CI -0.02 to 0.20) (ZVITAMBO Study Group); nor
at three and a half months (n = 402, MD 0.04 µmol/L, 95% CI
-0.01 to 0.09) or six months postpartum (n = 291, MD -0.02
µmol/L, 95% CI -0.08 to 0.04) in a study that had substantial
losses to follow-up (Ayah 2007). However, other smaller studies
that administered a single dose (200,000-300,000 IU)within three
weeks postpartum reported a statistically significant improvement
in serum retinol at three months compared with placebo (three
studies, n = 258,MD 0.17 µmol/L, 95%CI 0.06 to 0.28), but not
at six months (three studies, n = 260, MD 0.10 µmol/L, 95% CI
-0.02 to 0.23). Daily postpartum administration of 7.8 mg beta-
carotene did not improve maternal serum retinol concentrations
three, six or nine months after delivery in one small study (n = 71,
RETIBETA Project).
Vitamin A hepatic stores
Three studies analysed low vitamin A hepatic stores (reported as
relative dose response (RDR) greater than 20% or modified rela-
tive dose response (MRDR) > 0.06) at three, six, and nine months
postpartum (n = 315) - Analysis 1.10, Analysis 1.11, Analysis 1.12,
Analysis 1.13, Analysis 1.14. The RETIBETA Project reported an
improvement in the proportion of women with low hepatic stores
at three months (n = 69, MRDR > 0.06; RR 0.33, 95% CI 0.15 to
0.71) following a single 200,000 IU dose of vitamin A, compared
with placebo. In contrast, another small study (Stoltzfus 1993a)
did not report any difference in RDR greater than 20% three
months postpartum (n = 139, RR 1.15, 95% CI 0.41, 3.25). Nei-
ther study reported statistically significant differences when mea-
suring at six or months postpartum. No differences were reported
in the RETIBETA Project for this outcome between daily beta-
carotene supplementation (for nine months) and placebo at any
times, for example, when measured at nine months (n = 66, RR
0.61, 95% CI 0.30,1.23).
Breast milk retinol
Breast milk retinol levels were reported in several formats (retinol
concentration, proportion of milk retinol <1.05µmol/L or <0.28
µmol/gram of fat) in seven studies for a total of 1075 women
(Analysis 1.15 to Analysis 1.23 and Analysis 2.3). Vitamin A sup-
plementation (200,000-300,000 IU) was associated with an in-
creased breast milk retinol concentration at three to three and a
halfmonths (four studies, n = 390,MD0.27µmol/L, 95%CI 0.11
to 0.43) but this improvement was not sustained by six to six and
a half months postpartum. Supplementation with a single dose of
vitamin A (200,000-300,000 IU) significantly reduced the pro-
portion of women with low retinol concentration (<1.05µmol/L)
in human milk at three months (three studies, n = 373, RR 0.42,
95% CI 0.19 to 0.91), but not at six months after delivery (two
studies, n = 275, RR 0.65, 95% CI 0.23 to 1.90), compared with
placebo. Daily doses of beta-carotene to nine months postpartum
did not improve breast milk retinol at three or six months but
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did demonstrate improvement for this outcome by nine months
postpartum (n=135, MD 0.21µmol/L, 95% CI 0.04 to 0.38) in
the RETIBETA Project, compared with placebo.
Two studies (RETIBETA Project; WHO/CHD IVASSG) re-
ported the proportion of women with low breast milk retinol lev-
els (< 0.28 µmol/gram of fat; n = 479). Supplementation with
a single dose of vitamin A (200,000 IU) or daily beta-carotene
7.8mg daily for nine months did not improve this measure at three
months postpartum. Following supplementationwith 200,000 IU
demonstrated an improvement (two studies, n = 813, RR 0.84,
95% CI 0.71 to 0.99) at six months, which did not persist to
nine months (two studies, n = 699, RR 0.87, 95% 0.74 to 1.02).
Although no improvements were noted at three and six months
following daily administration of beta-carotene, an improvement
was noted by nine months (n = 134, RR 0.76, 95% CI 0.62 to
0.95).
Clinical and subclinical vitamin A deficiency
Stoltzfus 1993a measured abnormal conjunctival impression cy-
tology (CIC) in one or both eyes as the criterion for vitamin A
deficiency. There was no significant difference in the proportion of
women with abnormal CIC at six months postpartum, following
supplementation with vitamin A or placebo (n = 148, RR 0.56,
95% CI 0.27 to 1.17). However, they did reported a decline in
abnormal CIC from baseline (32.5%) to six months postpartum
(23.3%) following vitamin A supplementation (P < 0.006). No
such decline was recorded in the placebo group (27.6% at base-
line; 23.3% at six months) - Analysis 1.24, Analysis 1.25.
Anaemia
No studies addressed maternal anaemia.
Primary infant outcomes
Infant mortality
Infant mortality was assessed in four trials (Ayah 2007; Newton
2005; Venkatarao 1996; ZVITAMBO Study Group), with no dif-
ferences for vitamin A compared with placebo (RR 1.14 95% CI
0.84 to 1.57; 6170 infants - Analysis 1.26) or between different
dosing regimens (Analysis 2.1).
Infant morbidity
Three studies (Roy 1997; Venkatarao 1996; Vinutha 2000) eval-
uated infant morbidity in a total of 590 infants - Analysis 1.27 to
Analysis 1.33.
Diarrhoea
None of the three studies that considered diarrhoea or gastroen-
teritis reported any significant differences between the vitamin A
supplementation or control groups (Roy 1997 (n = 50, diarrhoea
episodes, P = 0.59), Venkatarao 1996 (n = 456, RR 1.02, 95% CI
0.98 to 1.06) and Vinutha 2000 (n = 84, RR 8.44, 95% CI 0.45,
158.4).
Respiratory illnesses
The reduction in observed reduced mean duration of acute res-
piratory tract infection (n = 50, 3.1 versus 3.7; P < 0.03) in the
treatment group reported by Roy 1997 was not noted in the larger
study by Venkatarao 1996, which reported no significant statisti-
cal difference in overall incidence of one or more episodes to 12
months of age of acute respiratory infection (n = 456, RR 1.00,
95% CI 0.96 to 1.03) between the supplemented and placebo
groups.
Febrile illness
One small study (Roy 1997) reported a lower mean number of
febrile illness episodes (n = 50, 0.1 versus 0.3, P < 0.002) in the
vitamin A group compared to the control group.
Adverse effects of vitamin A supplementation
No statistically significant differences were detected in the poten-
tial for developing the adverse effect of bulging fontanelle fol-
lowing vitamin A supplementation, including bulging fontanelle
(200,000 or 400,000 IU; n = 9622; RR 2.22 95% CI 1.01, 4.86)
- Analysis 1.34.
Secondary infant outcomes
Infant serum retinol
Four studies reported infant serum retinol between two and three
and a half months after birth (n = 454), with none demonstrating
a beneficial effect from any of the variety of dosing regimens used
- Analysis 1.35, Analysis 1.36. For example, the use of 400,000
IU versus placebo resulted in a MD of 0.02 µmol/L (n = 164,
95% CI -0.03 to 0.07) (Ayah 2007); or 400,000 versus 200,000
IU resulted in MD -0.02µmol/L (n = 134, 95% CI -0.05 to 0.09)
(Darboe 2007). There were no differences at five to six months by
any of the four studies that reported this outcome (Analysis 1.36,
n = 604), for example, the subgroup analysis of 200,000-300,000
IU versus placebo yielded a MD 0.04µmol/L (three studies, n =
324, 95% CI -0.01 to 0.09).
16Vitamin A supplementation for postpartum women (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vitamin A hepatic stores
Four studies reported low hepatic vitamin A stores (MRDR; n =
1128; Analysis 1.37, Analysis 1.38).
VitaminA hepatic stores analysed at six weeks, or five to sixmonths
of infancy were not enhanced by any vitamin A dosing regimens,
compared with placebo, for example, 200,000 IU versus placebo,
measured at six weeks of age (n = 600, RR 1.11, 95% CI 1.02
to1.21) (WHO/CHD IVASSG).
Clinical vitamin A deficiency
No studies addressed infant clinical vitamin A deficiency.
D I S C U S S I O N
Summary of main results
Maternal mortality was not influenced by single high-dose vita-
min A supplementation (400,000 IU) in two studies (Ayah 2007;
ZVITAMBO Study Group) conducted in areas of high maternal
mortality ratios (MMR): Zimbabwe (880/100,000) and Kenya
(560/100,000 live births). In contrast to our findings, one large
study carried out in Nepal that evaluated weekly long-term low-
dose supplementation with vitamin A or beta carotene (23,300
IU) for women during pregnancy and postpartum period demon-
strated a protective effect of vitamin A for maternal mortality
(NNIPS-2). However, more recently, other large studies from
Bangladesh (JivitA-1 Trial) and Ghana (ObaapaVitA) have not
been able to replicate this effect, which may relate to the different
maternal mortality ratios in these countries (Nepal 830/100,000;
Bangladesh 570/100,000 and Ghana 560/100,000 live births).
Infant mortality was not influenced by postpartum maternal vita-
minA supplementation (Ayah 2007;Darboe 2007;Newton 2005;
ZVITAMBO Study Group).
Several maternal morbidities are more prevalent in populations
known to be vitamin A deficient than in industrialised countries.
However, we did not observe a reduction in maternal morbid-
ity after supplementation. Only a protective effect of vitamin A
(300,000 IU) supplementation was observed in the prevalence
of abnormal conjunctival impression cytology, a measure that is
useful when there is restricted access to laboratory estimation of
vitamin A status, although not an ideal stand-alone indicator of
vitamin A deficiency (VAD) (Stoltzfus 1993b).
Maternal supplementation with a single postpartum dose of
200,000 IU vitamin A improved the proportion of women with
breast milk retinol content < 0.28 µmol/g of fat, compared with
placebo at six months after giving birth. This protective effect
was not observed in the pooled analysis including studies of mean
breast milk retinol (µmol/L).
Methodological studies suggest that the breast milk vitamin A
content expressed per gram of fat is a more responsive indicator
compared with serum retinol (Rice 2000; Stoltzfus 1993c). More-
over, serum retinol has some limitations as an indicator of vita-
min A status, because retinol binding protein is a negative acute
phase reactant protein (Filteau 1993; WHO 1996). Dancheck
2005 investigated the influence of acute phase reaction in breast
milk retinol concentration in women from Malawi. The authors
observed no significant differences in retinol breast milk concen-
tration between lactating women with or without signs of inflam-
mation. Thus, the meta-analysis results for breast milk retinol in
this review were probably more informative than serum retinol in
assessing the impact of vitamin A supplementation.
Although serum retinol concentration has some limitations as an
indicator, the Global WHO database on Vitamin A Deficiency, a
part of the Vitamin and Mineral Nutrition Information System
(VMNIS), compiles data on the prevalence of clinical VAD (night
blindness and ocular manifestation) and blood retinol concentra-
tion regularly from scientific literature and collaborators to esti-
mates the prevalence of VAD around the world. These estimates
provide valuable information for monitoring global progress and
for evaluating current strategies to reduce VAD (WHO 2009).
The pooled analysis of the reviewed studies showed that mater-
nal supplementation (200,000-300,000 IU) is associated with re-
duced proportions of low vitamin A hepatic stores and signifi-
cantly higher serum retinol concentration only until three months
postpartum.
There is a concern that maternal administration of 400,000 IU
within a single day might result in transient increases in breast
milk retinoic acids to toxic levels. For this reason, the Interna-
tional Vitamin A Consultative Group (Ross 2002) recommends
an interval of at least 24 hours between the two doses (200,000
IU each) for a total 400,000 IU vitamin A. Despite this recom-
mendation, the full 400,000 IU was administered as one dose in
two studies (ZVITAMBO Study Group; Ayah 2007), with no re-
ports of breast milk retinoic acid concentration immediately af-
ter supplementation. Although Darboe 2007 and Idindili 2007
supplemented the mothers with two doses of 200,000 IU with an
interval of 24 hours or one month, respectively, no data regarding
breast milk retinoic acid concentration were described. Studies of
VAD populations included in this review reported no increase in
signs and symptoms likely to be associated with raised intracranial
pressure among lactating women supplemented with high doses of
vitamin A, compared with placebo, including headaches, drowsi-
ness, nausea, vomiting or blurred vision.
This review did not find evidence of a protective effect in respect
of infant mortality. Only one small study reviewed observed sig-
nificant impact on infant morbidity (duration of acute respiratory
illness, number of febrile illnesses) (Roy 1997). In spite of the lack
of impact observed in this current review, other published meta-
analyses provide evidence that vitamin A supplementation in chil-
dren over six months of age may be associated with reduced risk
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of mortality frommeasles (Fawzi 1993; Yang 2005) and diarrhoea
(Glasziou 1993). The coexistence of multiple micronutrient de-
ficiencies could also be a factor that influenced the results. Ac-
cording to Rahman 2001, supplementation with zinc and vitamin
A is more effective than vitamin A supplementation alone in re-
duction of persistent diarrhoea and dysentery in children (one to
three years). Multiple-micronutrient supplementation to women
during pregnancy may improve outcomes such as fetal growth,
but infant outcomes including neurodevelopmental delay had not
been reported at the time of a systematic review by Haider 2006.
Further studies that consider fetal/neonatal/infant outcomes fol-
lowing maternal multiple-micronutrient supplementation during
pregnancy, breastfeeding, or both, may therefore be of interest.
A case-control study by Rondó 1997 conducted with Brazilian in-
fants observed that cord blood retinol concentration was higher in
infants with adequate growth for gestational age at delivery com-
pared with infants with intrauterine growth restriction. According
to the authors, one possible explanation for this result is mater-
nal VAD. In our review, we included one study (Ayah 2007) that
investigated the interaction of birthweight in the response to the
vitamin A supplementation, but the authors found no significant
effect. The studies included in this present systematic review did
not provide data in a format that would allow us to perform sub-
group analysis considering birthweight, although future studies
may consider this.
Co-existing vitamin A, iron and zinc deficiencies are important
and commonnutritional problems. There is evidence that zinc sta-
tus influences several aspects of vitamin A metabolism, including
absorption, transport and use (Christian 1998). Studies conducted
in rats noted that vitamin A metabolism is also altered with iron
deficiency, characterised by low serum retinol concentration and
increased vitamin A hepatic stores, probably associated with re-
duced retinyl ester hydrolase’s activity (Jang 2000; Oliveira 2008a;
Rosales 1999; Strube 2002). Clinical trials that combine two or
more micronutrients may be more effective in improving the nu-
tritional parameters compared to studies that use only one mi-
cronutrient (Dijkhuizen 2004; Rahman 2001; Suharno 1993). In
the present review, one trial supplemented the postpartum women
with vitamin A plus iron, compared to iron alone. In the vitamin
A plus iron group, the improvement on vitamin A status was evi-
dent only until three months postpartum. Although the maternal
serum retinol and breast milk concentration demonstrated a trend
toward improvement in the iron alone group at nine months, it
did not reach statistical significance (Roy 1997). In the trial by
Ayah 2007 a significant interaction between vitamin A supple-
mentation and serum ferritin was found. The authors observed
higher serum retinol among women with serum ferritin above 12
µg/L, suggesting that an improved iron status could influence the
response to vitamin A supplementation.
Regarding the infant hepatic vitamin A estimated stores, no pro-
tective effect of maternal vitamin A supplementation (200,000-
400,000 IU) was observed (Ayah 2007, RETIBETA Project;
Stoltzfus 1993a; WHO/CHD IVASSG).
Concern has been expressed about adverse effects from infant sup-
plementation with high doses of vitamin A (more than 50,000
IU; Allen 2002). Studies included in this review did not re-
port increased adverse signs and symptoms among infants sup-
plemented with doses ranging from 25,000-200,000 IU vitamin
A, or whose mothers received supplements. The lack of adverse
effects in women and babies following maternal vitamin A sup-
plementation is reassuring in the VAD populations studied. Such
reassurance cannot be assumed for other populations, including
many industrialised nations, where adequate vitamin A dietary in-
take is achieved.
Only one study monitored the vitamin A content in the capsules
during the trial and demonstrated that the vitamin content was
stable in the capsules administered to the women. However, the
lower dose capsules administered to infants (results not included in
this review) were subject to deterioration over time by up to 32%
of expected content (Idindili 2007). Thus, the stability of vitamin
A capsules should be considered in further studies and routine
supplementation programmes (Idindili 2007; Newton 2008).
Four studies (Ayah 2007; Darboe 2007; Idindili 2007;
ZVITAMBO Study Group) assessed the effects of a higher dose
of vitamin A (400,000 IU). Two of them evaluated the effects of
two high doses of 200,000 IU vitamin A (400,000 IU) versus one
dose (200,000 IU) and no improvement in maternal and infant
health were observed. The remaining studies compared the higher
dose (400,000 IU) with placebo and did not report a significant
impact on maternal health.
Overall completeness and applicability of
evidence
Although included studieswere conducted in areas ofVAD(WHO
2009), in most of the studies the baseline mean maternal serum
concentrations were above the cutoff point proposed by WHO
(WHO 1996). Despite this, our findings may be interpreted to
represent chronic inadequate vitamin A stores for mothers’ health
needs, which translated to infants born with inadequate stores.
This sub-optimal ’starting point’ could not be corrected by post-
partum administration of vitamin A to mothers, specifically when
breastfeeding. Other systematic reviews of long-term supplemen-
tation to women during their reproductive years (including the
postpartum period) and of infant supplementation may exam-
ine whether long-term preventive supplementation confers greater
benefits than postpartum supplementation, that is, after the time
when the infant has already received inadequate provision of vita-
min A during pregnancy (Haider 2006; Van den Broek 2002).
Quality of the evidence
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We judged the included trials to have an overall moderate risk of
bias. However we also judged that any bias was unlikely to have
obscured a true effect of vitamin A (should it have existed).
Potential biases in the review process
We used several approaches in an attempt to minimise bias. The
search strategy incorporated both the trials register of theCochrane
Pregnancy and Childbirth Group and other databases that were
likely to included publications from less well developed coun-
tries that may not be identified through standard searches. The
review authors independently assessed eligibility for conclusion,
conducted data extraction and negotiated on areas of concern or
uncertainty. Considering the high number of meta-analyses, there
is a risk of spuriously significant results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In countries with widespread breastfeeding practices and high
prevalences of vitamin A deficiency, the transient improvement in
maternal serum retinol concentration andmilk retinol represent at
least a limited benefit of vitamin A supplementation for postpar-
tum women. These findings need to be considered in the context
of the potential for follow up with longer term supplementation
to ultimately improve maternal and infant health outcomes.
No vitamin A supplementation regimens report adverse effects for
infants or their mothers, in regions of vitamin A deficiency.
This review has not evaluated vitamin A supplementation in non-
deficient populations.
Implications for research
This review’s focus on postpartum supplementation needs to be
considered as part of a wider focus on vitamin A status during
infancy and for women, across their reproductive years, including
the ideal dosing regimen to achieve improved maternal and infant
health for those residing in countries of vitaminAdeficiency,where
there are also high rates ofmaternal and infantmortality.Moreover,
the stability of vitamin A content in capsules needs consideration.
Further research may consider the potential interaction between
vitamin A and other micronutrients, including iron and zinc.
Other sustainable long-term strategies to achieve food security, as
increased access to local vitamin A rich foods and nutritional ed-
ucation, are also recommended.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ayah 2007
Methods Randomised, double blind, placebo controlled, 2 by 2 factorial trial
Participants Women giving birth to a live single baby and their infants.
Bondo, Kenya.
N = 564 mothers and their infants.
Interventions Single dosage administered to mother within 24 hours of birth; single dosage to infant
at 1-4 weeks of age
All infants received 100,000 IU vitamin A at 8 months of age (after trial)
4 intervention groups:
1. Mother received 400,000 IU vitamin A and infant received 100,000 IU vitamin A as
retinyl palmitate (n = 142).
2. Mother received 400,000 IU vitamin A and infant received placebo (n = 140).
3. Mother received placebo and infant received 100,000 IU vitamin A (n = 143).
4. Mother received placebo and infant received placebo (n = 139)
Outcomes Maternal serum retinol concentration, breast milk retinol concentration. Infant serum
retinol concentration, vitamin A hepatic stores (MRDR)
Notes No information regarding breastfeeding pattern was provided. However, at least some
breastfeeding is implied by the analysis of breast milk retinol at 6 months for 63% of
the women originally enrolled
87.4% of follow up until 14 weeks, 77.1% of follow up until 26 weeks postpartum
The prevalence of HIV infection among antenatal attendees was above 28% at the time
of the study. However, the trial was conducted prior to availability of HIV testing and
antiretrovirals for antenatal women in western Kenya. Thus, it was not possible to know
the prevalence of HIV among recruited women
Sample size calculation reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Two random sequences of X and Y were
prepared, one for the mothers and one for
the infants. Identification numbers from
1 to 700 were assigned consecutively to
each of the two lists and mother-infant
pairs of capsules were packaged in zip-lock
bags numbered from 1 to 700 and kept in
batches of ten.”
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Ayah 2007 (Continued)
Allocation concealment? Low risk “The randomisation codes were concealed
for the entire trial duration and only re-
vealed after completion of data analysis.”
Blinding?
All outcomes
Low risk “...prepared and supplied the vitamin A
and identical-looking placebo supplements
as oily capsules in brown bottles coded as
X or Y.”
Incomplete outcome data addressed?
All outcomes
Low risk All analyses were by intention-to-treat.
Free of selective reporting? High risk Not all clinically relevant outcomes re-
ported.
Free of other bias? High risk Supported by Hoffmann-La Roche Ltd
(Basel Switzerland).
Bhaskaram 2000
Methods Randomised, double blind, placebo controlled trial.
Participants Hospital based study with postpartum women who did not receive any vitamin A sup-
plements during pregnancy and had uncomplicated full term births
Hyderabad, India.
102 mothers and their infants.
Interventions Single high dose to mother within 24 hours after birth.
2 intervention groups:
1. Mother received 200,000 IU vitamin A as retinyl palmitate (n = 50).
2. Mother received placebo (n = 52).
Outcomes Infant serum retinol concentration, breastmilk retinol concentration, and corneal lesions
Notes All babies given oral polio vaccine within 72 hours after birth.
All infants breastfed, followed up at 6 months.
100% of follow up until 6 weeks, 87% followed up until 3 months, 46% followed up
until 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Randomised, no detail provided.
Allocation concealment? Unclear risk No detail provided.
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Bhaskaram 2000 (Continued)
Blinding?
All outcomes
Low risk Blinding: vitamin A and placebo coded by
person not connected with the investiga-
tion.
Nurse administering dose unaware of code.
Incomplete outcome data addressed?
All outcomes
High risk Reasons for attrition and exclusions not re-
ported. Intention-to-treat analyses not per-
formed
Free of selective reporting? High risk Not all clinically relevant outcomes re-
ported.
Free of other bias? Unclear risk Source of funding not mentioned. No
mention of any research protocol published
a priori
Darboe 2007
Methods Randomised, double blind, placebo controlled trial.
Participants Postpartum women without severe peripartum difficulties or preterm birth, with new-
borns ≥ 2200 g with no congenital defects at birth
Keneba and West Kiang, Gambia.
220 mothers and their infants.
Interventions Single or double high dose to mother at delivery (first dose) and within a week (second
dose); and 3 high doses to infant at 2, 3 or 4 months
All infants received 100,000 IU vitamin A at 9 months and 200,000 IU at 12 months
postpartum
2 intervention groups:
1. Mother received 400,000 IU vitamin A as retinyl palmitate and infant received 150,
000 IU vitamin A (3 doses of 50,000 IU) (n = 110);
2. Mother received 200,000 IU and infant received placebo (3 doses) (n = 110)
Outcomes Maternal morbidity, and serum retinol and breast milk retinol concentration. Infant
morbidity, haemoglobin concentration, and serum retinol concentration
Notes No information regarding breastfeeding pattern was provided. However, at least partial
breastfeeding is implied by the reported analysis of breast milk retinol to 6 months in
88% of those enrolled
89.5% of follow up until 12 months.
Risk of bias
Bias Authors’ judgement Support for judgement
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Darboe 2007 (Continued)
Adequate sequence generation? Low risk “An independent senior scientist packed
and labelled the supplements, and did a
block randomisation procedure (16 per
block) to allow for possible effects of season
of
birth.”
Allocation concealment? Low risk “All members of the trial team were un-
aware of allocation until the data had been
cleaned and locked.”
Blinding?
All outcomes
Unclear risk “Vitamin A in vegetable oil and vegetable
oil placebo were prepared by Hoffmann La
Roche (Basel, Switzerland).”
Incomplete outcome data addressed?
All outcomes
Low risk Reasons for attrition and exclusions were
reported in detail, although intention-to-
treat analysis was not performed
Free of selective reporting? High risk Not all clinically relevant outcomes re-
ported
Free of other bias? Low risk Trial registered a priori (No. ISRCTN
98554309). The UK Medical Research
Council funded the study, and laboratory
analyses in Coleraine were supported by
BASF
Aktiengesellschaft (Ludwigshafen, Ger-
many).
Idindili 2007
Methods Randomised, double blind, placebo controlled trial.
Participants Mothers resident in the study area that brought their infants for vaccination
Ifakara, Tanzania.
780 mothers and their infants.
Interventions Single or double high dose to mother within 1 week after delivery; and 3 standard or
higher doses to infant at 1, 2 or 3 months (DPT/OPV vaccination)
All infants received 100,000 IU vitamin A at measles vaccination (9 months)
2 intervention groups:
1. Mother received 200,000 IU vitamin A as retinyl palmitate and infant received 75,
000 IU vitamin A (3 doses of 25,000 IU) (n = 390).
2. Mother received 400,000 IU vitamin A and infant received 150,000 IU vitamin A (3
doses of 50,000 IU) (n = 390)
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Idindili 2007 (Continued)
Outcomes Infant morbidity, anaemia (packed cell volume), serum retinol concentration, vitamin
A hepatic stores (MRDR), and breast milk retinol concentration
Notes At least 86% of infants were exclusively breastfed until 1 month
81% of follow up until 3 months; 79.5% until 6 months; and 77.2% until 9 months
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Individual randomizationwas achieved by
using a list of study numbers that had been
randomly assigned to an intervention arm
in blocks of 10, generated by the Data and
Safety Monitoring Board.”
Allocation concealment? Low risk “A compact disk containing the cleaned
and locked database files was exchanged for
the treatment randomization code, held by
the Data and Safety Monitoring Board.”
All members of the trial team were un-
aware of allocation until the data had been
cleaned and locked
Blinding?
All outcomes
Unclear risk “Vitamin A capsules providing different
doses were manufactured by Accucaps In-
dustries (Windsor, Canada) (25,000 and
50,000 IU) and RpScherer (Aprilia, Italy)
(200,000 IU), and were supplied to the
project by the WHO.”
Not enough detail to judge whether partic-
ipants were blinded
Incomplete outcome data addressed?
All outcomes
High risk Reasons for attrition and exclusions not re-
ported. Intention-to-treat analyses not per-
formed
Free of selective reporting? High risk Not all clinically relevant outcomes re-
ported.
Free of other bias? Unclear risk Post hoc analyses were conducted because
of concerns that the capsules did not con-
tain the necessary amount of vitamin A (in
a sample of capsules vitamin degraded)
Supported by Immunization Vaccines &
Biologicals (the World Health Organi-
zation and the United Nations Foun-
dation), Sight&Life (Hoffman-la Roche
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Idindili 2007 (Continued)
Ltd), Micronutrient Initiative, the Cana-
dian International Development Agency,
and the United Nations Children’s Fund
(UNICEF)
Newton 2005
Methods Randomised, double blind, placebo controlled 2 x 2 factorial design trial
Participants Women 3-4 weeks postpartum and their infants.
Kintampo, Brong Ahafo Region, Ghana.
N = 1085 mothers and their infants.
Interventions 4 intervention groups.
1. Mother received 200,000 IU of vitamin A as retinyl palmitate at 3-4 weeks and infant
received total of 75,000 IU (25,000 IU at 6, 10 and 14 weeks) (n = 274)
2. Mother received placebo at 3-4 weeks and infant received total of 75,000 IU (25,000
IU at 6, 10 and 14 weeks) (n = 265)
3. Mother received 200,000 IU of vitamin A as retinyl palmitate and infant received
total of placebo (n = 269)
4. Mother received placebo and infant received placebo at 6, 10 and 14 weeks (n = 277)
Outcomes Infant serum antibody titers for polio and tetanus at 6months of age, and infantmortality
Notes No information supplied regarding breastfeeding rates. The report’s background out-
lined the evaluation of whether maternal supplementation alone could achieve adequate
vitamin A status, without the need for infant supplementation. This suggests that women
were breastfeeding
Infant supplementation linked to time of administration of diphtheria pertussis tetanus
and polio vaccinations
It was confirmed with the first author that the mortality data in the study referred to
infants
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Mothers and infants were allocated to 1 of
4 treatment groups, using
a blocked randomization scheme.”
Allocation concealment? Unclear risk Details not provided.
Blinding?
All outcomes
Low risk “The test and placebo capsules were iden-
tical in size colour and shape.”
Incomplete outcome data addressed?
All outcomes
High risk Only infants of mothers for which blood
sample was obtained in the end of the study
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Newton 2005 (Continued)
were included in the analysis. Attrition was
34.6%
Free of selective reporting? High risk Not all clinically relevant outcomes were
reported.
Free of other bias? Unclear risk Enrolment of participants was extended to
higher thanplanned lost to follow-up. Sam-
ple size calculation provided, but unclear
whether a protocol was published a priori.
Supported by a grant from the Wellcome
Trust
RETIBETA Project
Methods Randomised, double blind, placebo controlled trial.
Participants Community-based study with women at 1-3 weeks after birth.
Matlab, Bangladesh.
220 mothers and their infants.
Interventions Single high dose to mother within 1-3 weeks after delivery of beta-carotene daily for 9
months
3 intervention groups:
1. Mother received 200,000 IU of vitamin A as retinyl palmitate and placebo daily for
9 months postpartum (n = 74).
2. Mother received placebo and 7.8 mg (1,300 µg RE or 4,327 IU) of beta-carotene
daily until 9 months postpartum (n = 73).
3. Mother received placebo and placebo daily until 9 months postpartum (n = 73)
Outcomes Maternal serum retinol, vitamin A hepatic stores (MRDR), and breast milk retinol con-
centration. Infant serum retinol concentrations, and vitamin A hepatic stores (MRDR)
in a subsample of mothers and infants
Notes All Infants at least partially breastfed to 6 months of age.
87% ate complementary food during this period.
98% follow-up rates until 3 months, 95% until 6 months, and 92% until 9 months
postpartum
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Before beginning the study, individual
treatment codes and follow-up schedules
were assigned to a sequence of identifi-
cation numbers in blocks of 18 using a
random number table”...“Each block con-
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RETIBETA Project (Continued)
tained all possible combinations of three
treatment groups.”
Allocation concealment? Low risk “The study capsules were manufactured by
Tischon Corporation (Salisbury, MD) and
delivered to the field and to study partici-
pants coded as type A, B or C.”
Blinding?
All outcomes
Low risk Capsules: packaged in blister pack strips.
Vitamin A and placebo capsules differed
in colour slightly - authors considered that
foil packagingwould reduce direct compar-
isons between groups. Beta-carotene and
placebo capsules identical in colour
Incomplete outcome data addressed?
All outcomes
High risk Reasons for attrition and exclusions not re-
ported. Intention-to-treat analyses not per-
formed
Free of selective reporting? High risk Not all clinically relevant outcomes were
reported.
Free of other bias? Unclear risk Supported by cooperative agreements be-
tween The Johns Hopkins University
School of Hygiene and Public Health, Bal-
timore,MD, USA and theOffice of Health
and Nutrition, U.S. Agency for Inter-
national Development, Washington, DC
(DAN-5116-1-00-8051-00 and HRN-A-
00-97-00015-00). Research protocol not
published a priori
Roy 1997
Methods Randomised controlled trial.
Participants Postpartum women.
Dhaka, Bangladesh.
50 mothers and their infants.
Interventions Single high dose to mother within 24 hours after birth.
2 intervention groups:
1. Mother received 200,000 IU vitamin A as retinyl palmitate plus 60 mg of iron daily
for 9 months (n = 25).
2. Mother received 60 mg of iron daily for 9 months (n = 25)
Outcomes Maternal serum retinol, and breast milk retinol concentration. Infant morbidity
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Roy 1997 (Continued)
Notes All babies were breastfed until 6 months postpartum.
No information regarding breastfeeding pattern was provided.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Women were randomly allocated to either the interven-
tion or control group. No further details provided
Allocation concealment? Unclear risk No details provided.
Blinding?
All outcomes
High risk Women in the control group did not receive a placebo.
No details provided about blinding of field workers, lab-
oratory staff or investigators
Incomplete outcome data addressed?
All outcomes
Low risk All randomised participants were accounted for in the
analysis
Free of selective reporting? High risk Not all clinically relevant outcomes were reported.
Free of other bias? Unclear risk Study supported by the International Centre for Diar-
rhoeal Disease Research and the United States Agency
for International Development. Research protocol not
published a priori
Stoltzfus 1993a
Methods Randomised, double blind, placebo controlled trial.
Participants Women at 1-3 weeks postpartum.
Java, Indonesia.
153 mothers and their infants.
Interventions Single high dose to mother within 1-3 weeks after birth.
2 intervention groups:
1. Mother received 300,000 IU vitamin A as retinyl palmitate (n = 77)
2. Mother received placebo (n = 76).
Outcomes Maternal abnormal conjunctival impression cytology (CIC), breast milk retinol con-
centration, maternal serum retinol concentration. Infant serum retinol concentration,
vitamin A hepatic stores (RDR)
Notes No specific information regarding breastfeeding pattern was provided. However, the
report’s title, background and analysis of breast milk retinol to 8 months postpartum
strongly suggest that infants received at least some breast milk for the duration of the
study. Additionally, it is noted that the 3 women who stopped breastfeeding were not
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Stoltzfus 1993a (Continued)
included in the 6 month follow-up
88.9% follow-up rate until 6 months postpartum.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Individual randomization to treatment
codes A and B was done in blocks of eight
according to the Moses-Oakford assign-
ment algorithm.”
Allocation concealment? Low risk “The allocation of treatment codes A and B
to vitamin A or placebo capsules was done
by the Sight and Life Task Force, Hoff-
mann-LaRoche (Basel, Switzerland), who
prepared the capsules.”
Blinding?
All outcomes
Low risk Vitamin A and placebo capsules “looked
practically identical” and were prepared by
“Sight and Life Task Force, Hoffmann-
LaRoche” - in labelled foil packs. Partici-
pants, field workers, investigators and lab-
oratory staff blinded to randomisation se-
quence until after field work complete
Incomplete outcome data addressed?
All outcomes
High risk Reasons for attrition and exclusions not re-
ported. Intention-to-treat analyses not per-
formed
Free of selective reporting? High risk Not all clinically relevant outcomes were
reported.
Free of other bias? Unclear risk Supported by a grant from theThrasherRe-
search Fund and a National Science Foun-
dation Graduate Fellowship to Rebecca I.
Stoltzfus. Study protocol not published a
priori
Venkatarao 1996
Methods Randomised, double blind, placebo controlled trial.
Participants Women at 1-2 weeks after birth.
Tamil Nadu, India.
909 mothers and their infants.
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Venkatarao 1996 (Continued)
Interventions Single high dose to mother within 1-2 weeks after birth; and high dose to infant at 6
months
3 intervention groups:
1. Mother received 300,000 IU vitamin A as retinyl palmitate and Infant received 200,
000 IU vitamin A (n = 301)
2. Mother received 300,000 IU vitamin A and Infant received placebo (n = 297)
3. Mother received placebo and Infant received placebo at 6 months of age (n = 311)
Outcomes Infant morbidity, and adverse effects.
Notes 99.7% of infants were breast fed for at least 6 months. No information regarding breast-
feeding pattern was provided
75.8% follow-up rate until 12 months postpartum.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “...randomly allocated”. No further details
given.
Allocation concealment? Unclear risk “ theMedicalOfficer...administered the ap-
propriate capsules to the mother from the
sealed envelope supplied by the Statistical
Section at the Camp Office.”
Blinding?
All outcomes
Low risk Capsules were “similar in colour”. Infant
syrup matched for colour and consistency
Incomplete outcome data addressed?
All outcomes
High risk Exclusions and attrition were 23%. Inten-
tion-to-treat analyses not performed
Free of selective reporting? High risk Not all expected outcomes reported.
Free of other bias? Unclear risk Source of funding not provided. No men-
tion of research protocol
Vinutha 2000
Methods Randomised, controlled trial.
Participants Postpartum women (primigravid and second-gravid).
Mumbai, India.
109 mothers and their infants.
Interventions Single high dose to mother within 48 hours after delivery.
2 intervention groups:
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Vinutha 2000 (Continued)
1. Mother received 200,000 IU vitamin A as aquasol water miscible (n = 53)
2. Mother did not receive vitamin A or placebo (n = 56).
Outcomes Maternal serum retinol, breast milk retinol concentration. Infant serum retinol concen-
tration
Notes All babies were exclusively breastfed.
77.1% follow-up rate until 3 months postpartum.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Randomised. No further details provided.
Allocation concealment? Unclear risk No details provided.
Blinding?
All outcomes
High risk Women in the control group did not receive a placebo.
No other details provided on blinding
Incomplete outcome data addressed?
All outcomes
High risk Reasons for attrition and exclusions not reported. In-
tention-to-treat analyses not performed
Free of selective reporting? High risk Not all clinically relevant outcomes were reported.
Free of other bias? Unclear risk Fundedby the LokmanyaTilakMunicipalMedical Col-
lege and Hospital in Mumbai. Study protocol not pub-
lished a priori
WHO/CHD IVASSG
Methods Randomised, double blind, placebo controlled, multicentre trial (India, Ghana, and
Peru)
Participants Postpartum women and their infants.
New Delhi, India; Brong Ahafo, Ghana; Lima, Peru.
7078 mothers and their infants.
Interventions Single high dose to mother within 21-42 days after birth in Ghana and 18-28 days after
birth in Peru and India
3 doses to infant during their DPT or OPV immunization (6, 10, 14 weeks) in Ghana,
India and (2, 3 and 4 months) in Peru
Multicentre trial - At 9 months, infants received 25,000 IU vitamin A with measles
immunisation and infants from the control group received single high dose 100,000 IU
vitamin A
Ghana trial - At 6 months, infants received 25,000 IU vitamin A and infants from the
control group received single high dose 100,000 IU vitamin A
Multicentre trial - 2 intervention groups:
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WHO/CHD IVASSG (Continued)
1. Mother received 200,000 IU vitamin A as retinyl palmitate and Infants received 100,
000 IU vitamin A (4 doses 25,000 IU) (n = 3,522)
2. Mothers received placebo and Infants received placebo (3 doses) plus 100,000 IU
vitamin A at 9 months (equivalent total dose received by group 1) (n = 3,556)
Ghana - 4 intervention groups:
1. Mother received 200,000 IU vitamin A as retinyl palmitate and Infants received 100,
000 IU vitamin A (4 doses 25,000 IU) (n = 196).
2. Mother received placebo and Infants received vitamin A as per group 1 (n = 192).
3. Mother received vitamin A as per group 1 and Infants received placebo at times of
immunisation, plus 100,000 IU vitamin A at 6 months (equivalent total dose received
by groups 1 and 2) (n = 185).
4. Mothers received placebo and Infants received placebo (3 doses), plus 100,000 IU
vitamin A at 6 months (equivalent total dose received by groups 1 and 2) (n = 194)
Outcomes Maternal serum retinol, breast milk retinol concentration. Infant mortality, morbidity,
acute toxic effects, serum retinol concentration, vitamin A hepatic stores (MRDR)
Notes At least 99.4% of infants were breastfed at enrolment. The sub-study that reported
breast milk retinol gave these findings for 570 women, compared with 631 at 2 months,
suggesting that the majority of infants were at least partially breast fed to 9 months
74.9% follow-up rate until 12 months postpartum.
Before and periodically during the study standardisation exercises to assess agreement
within and between observers were conducted for the main outcome variables
Standardisation across sites (Ghana, India and Peru) was ensured by exchange visits
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Identification numbers were generated by
computer at the data management centre
at John Hopkins University in Baltimore,
and assigned as random permuted blocks
of size eight.”
Allocation concealment? Low risk “Three sealed copies of study codes were
prepared and kept at WHO in Geneva,
with the ethics committee of the All In-
dia Institute of Medical Sciences in New
Delhi, and at the data management centre
inBaltimore. Accesswas limited to one data
manager, who had no direct involvement in
the data analysis, and who prepared infor-
mation requested by the treatment effects
monitoring committee.”
Blinding?
All outcomes
Low risk “The supplements and placebo, in identi-
cal opaque gelatin capsules, were packaged
in individually coded blister packs in Bal-
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WHO/CHD IVASSG (Continued)
timore.”
Incomplete outcome data addressed?
All outcomes
Low risk “All analyses were by intent to treat from
the time of first administration of study
capsule to the mother.”
Free of selective reporting? Low risk All expected clinically relevant outcomes
were reported.
Free of other bias? Low risk Trial supported by the Child Health and
DevelopmentDivision ofWHO, the Johns
Hopkins Family Health and Child Survival
Cooperative Agreement (HRN 5986-A-
00-6006-00)with funding from theUnited
States Agency for International Develop-
ment, and the Indian Council of Medical
Research. A study protocol was not men-
tioned but study described in detail
ZVITAMBO Study Group
Methods Randomised, double blind, placebo controlled, 2 by 2 factorial trial
Participants Postpartum women without a life-threatening condition and their infants with birth-
weight ≥ 1500 g from urban maternity centres.
Harare, Zimbabwe.
N = 14,110 mothers and their infants.
Interventions Double high dose to mother within 96 hours of birth and single high dose to infant
4 treatment groups:
1. Mother received 400,000 IU vitamin A as retinyl palmitate and infant received 50,
000 IU vitamin A (n = 3529)
2. Mother received 400,000 IU vitamin A and infant received placebo (n = 3529)
3. Mother received placebo and infant received 50,000 IU vitamin A (n = 3530)
4. Mother received placebo and infant received placebo (n = 3522)
Outcomes Maternalmortality,morbidity, serum retinol concentration, haemoglobin concentration.
Infant mortality, acute adverse effects (for 788 mother-infant pairs only), and serum
retinol concentration
Infant cause of death was determined from medical records when the death occurred in
the hospital, or from a review of verbal autopsy information by study paediatrician
Notes All women initiated breastfeeding (97% started breastfeeding within 12 hours postpar-
tum). 99.5% were still breastfeeding at 6 months and 85.8% at 12 months postpartum
Risk of bias
Bias Authors’ judgement Support for judgement
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ZVITAMBO Study Group (Continued)
Adequate sequence generation? Low risk “A separate team at Johns Hopkins Uni-
versity prepared the study capsule pack-
ets. Study identification numbers were ran-
domly allocated to the treatment groups
by computer in blocks of 12. The num-
bers were printed on adhesive labels and af-
fixed to amber-colored zip-lock plastic bags
that were packed with the assigned cap-
sules. Capsule packets were prepared sep-
arately for each of the 4 treatment groups
and were then merged into numeric order
before shipping to Zimbabwe, where a se-
ries of packets were distributed to each re-
cruitment site. As each mother-infant pair
was recruited, the capsules in the next se-
quential bag were administered, and the as-
sociated study number was assigned to the
pair.”
Allocation concealment? Low risk “Lists linking the study number to the
treatmentwere kept in sealed envelopes and
encrypted computer files.”
Blinding?
All outcomes
Low risk “Treatment and placebo capsules appeared
identical.”
“separate team at Johns Hopkins Univer-
sity prepared the study capsule packets”
and “neither participants nor nurses who
administered the capsules or assessed out-
comes were aware of treatment group as-
signment.”
Incomplete outcome data addressed?
All outcomes
High risk “Only infants of mothers who remained
HIV-negative to 12 months postpartum
were included in the current analysis.”
Attrition was 11.3% (in both the vitamin
A and placebo groups) for HIV-negative
women (985/9562)
Adverse event data was only available for a
subset of 788 mother-infant pairs
The analyses were not by ITT.
Free of selective reporting? High risk Not all clinically relevant outcomes were
reported.
Free of other bias? Low risk “The ZVITAMBO Project was primarily
supported by the Canadian International
Development Agency (R/C Project 690/
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ZVITAMBO Study Group (Continued)
M3688), the US Agency for International
Development (cooperative agreement no.
HRN-A-00-97-00015-00 between Johns
Hopkins University and the Office of
Health and Nutrition of the USAID), and
a grant from the Bill and Melinda Gates
Foundation (Seattle); additional support
was provided by the Rockefeller Founda-
tion (NewYork) and BASF (Ludwigshafen,
Germany).”
CIC: conjunctival impression cytology
DPT: diphtheria, pertussis, tetanus vaccine
h: hour
IU: international unit
MRDR: modified relative dose response
OPV: oral polio vaccine
RE: Retinol equivalent
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ala-Houhala 1988 Alternate allocation to the control or test group.
Basu 2003 Alternate allocation to the control or test group.
Bezerra 2010 Alternate allocation to the control or test group.
Canfield 2001 Provision of vitamin A rich foods rather than vitamin A supplements
De Pee 1995 Provision of vitamin A rich foods rather than vitamin A supplements
Filteau 1999 Provision of vitamin A rich foods rather than vitamin A supplements
Gossage 2000 Provision of vitamin A rich foods rather than vitamin A supplements
Khan 2007 Provision of vitamin A rich foods rather than vitamin A supplements
Lietz 2001 Provision of vitamin A rich foods rather than vitamin A supplements
Lietz 2006 Provision of vitamin A rich foods rather than vitamin A supplements
Ncube 2001 Provision of vitamin A rich foods rather than vitamin A supplements
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(Continued)
NNIPS-2 Long-term supplementation for women of reproductive age.
ObaapaVitA Long-term supplementation for women of reproductive age.
Tchum 2006 Alternate allocation to the control or test group.
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D A T A A N D A N A L Y S E S
Comparison 1. Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no
treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1Maternal mortality to six months 1 564 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.09, 2.71]
1.1 400,000 IU versus placebo 1 564 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.09, 2.71]
2 Maternal fever at 3 months
postpartum
Other data No numeric data
2.1 200,000 IU versus no
treatment
Other data No numeric data
3 Maternal respiratory tract
infection at 3 months
postpartum
Other data No numeric data
3.1 200,000 IU versus no
treatment
Other data No numeric data
4 Maternal diarrhoea at 3 months
postpartum
Other data No numeric data
4.1 200,000 IU versus no
treatment
Other data No numeric data
5 Maternal adverse effects of
supplementation
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Headache within 30 hours
of dosing: 400,000 IU versus
placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.74, 1.99]
5.2 Blurred vision within 30
hours of dosing: 400,000 IU
versus placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.39, 6.82]
5.3 Drowsiness within 30
hours of dosing: 400,000 IU
versus placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [0.91, 4.79]
5.4 Nausea within 30 hours
of dosing: 400,000 IU versus
placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.44, 4.31]
5.5 Vomiting within 30 hours
of dosing: 400,000 IU versus
placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.14]
5.6 Poor appetite within 30
hours of dosing: 400,000 IU
versus placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 2.22 [0.69, 7.14]
5.7 Abdominal pain within 30
hours of dosing: 400,000 IU
versus placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.95, 1.73]
6Maternal serum retinol (µmol/L)
at 1.5 months postpartum
1 260 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.02, 0.20]
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6.1 HIV negative women:
400,000 IU versus placebo
1 260 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.02, 0.20]
7 Maternal serum retinol
(mcmol/L) at 3 - 3.5 months
postpartum
4 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 200,000-400,000 IU
versus placebo or no treatment
4 660 Mean Difference (IV, Random, 95% CI) 0.11 [0.01, 0.20]
7.2 200,000-300,000 IU
versus placebo or no treatment
3 258 Mean Difference (IV, Random, 95% CI) 0.17 [0.06, 0.28]
7.3 400,000 IU versus placebo 1 402 Mean Difference (IV, Random, 95% CI) 0.04 [-0.01, 0.09]
7.4 Beta-carotene: 7.8 mg
daily versus placebo
1 71 Mean Difference (IV, Random, 95% CI) 0.10 [-0.10, 0.30]
8 Maternal serum retinol
(mcmol/L) at 6 - 6.5 months
postpartum
4 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 200,000-400,000 IU
versus placebo or no treatment
4 551 Mean Difference (IV, Random, 95% CI) 0.05 [-0.07, 0.17]
8.2 200,000-300,000 IU
versus placebo or no treatment
3 260 Mean Difference (IV, Random, 95% CI) 0.10 [-0.02, 0.23]
8.3 400,000 IU versus placebo 1 291 Mean Difference (IV, Random, 95% CI) -0.02 [-0.08, 0.04]
8.4 beta-carotene: 7.8mg daily
versus placebo
1 68 Mean Difference (IV, Random, 95% CI) 0.05 [-0.22, 0.32]
9 Maternal serum retinol
(mcmol/L) at 9 months
postpartum
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 200,000-300,000 IU
versus placebo or no treatment
2 113 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.13, 0.17]
9.2 beta-carotene: 7.8mg daily
versus placebo
1 66 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.03, 0.41]
10 Maternal low hepatic vitamin
A stores 3 months postpartum
(MRDR ≥ 0.06)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 200,000 IU versus
placebo
1 69 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.15, 0.71]
10.2 beta-carotene: 7.8 mg
daily versus placebo
1 71 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.47, 1.26]
11 Maternal low hepatic vitamin A
stores 5 - 6 months postpartum
(MRDR ≥ 0.06)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 200,000 IU versus
placebo
1 71 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.48, 1.85]
11.2 beta-carotene: 7.8 mg
daily versus placebo
1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.24, 1.32]
12 Maternal low hepatic vitamin
A stores 9 months postpartum
(MRDR ≥ 0.06)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 200,000 IU versus
placebo
1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.34, 1.34]
12.2 beta-carotene: 7.8 mg
daily versus placebo
1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.30, 1.23]
42Vitamin A supplementation for postpartum women (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13 Maternal low hepatic vitamin
A stores 3 months postpartum
(RDR > 20%)
1 139 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.41, 3.25]
13.1 300,000 IU versus
placebo
1 139 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.41, 3.25]
14 Maternal low hepatic vitamin
A stores 6 months postpartum
(RDR > 20%)
1 139 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [0.20, 23.16]
14.1 300,000 IU versus
placebo
1 139 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [0.20, 23.16]
15 Breast milk retinol (mcmol/L)
at 3 - 3.5 months postpartum
5 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 200,000-400,000 IU
versus placebo no treatment
5 812 Mean Difference (IV, Random, 95% CI) 0.20 [0.08, 0.33]
15.2 200,000-300,000 IU
versus placebo no treatment
4 390 Mean Difference (IV, Random, 95% CI) 0.27 [0.11, 0.43]
15.3 400,000 IU versus
placebo
1 422 Mean Difference (IV, Random, 95% CI) 0.08 [0.03, 0.13]
15.4 beta-carotene: 7.8 mg
daily versus placebo
1 145 Mean Difference (IV, Random, 95% CI) 0.02 [-0.14, 0.18]
16 Breast milk retinol (mcmol/L)
at 6 - 6.5 months postpartum
4 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 200,000-400,000 IU
versus placebo or no treatment
4 679 Mean Difference (IV, Random, 95% CI) 0.19 [-0.01, 0.39]
16.2 200,000-300,000 IU
versus placebo or no treatment
3 325 Mean Difference (IV, Random, 95% CI) 0.27 [-0.05, 0.60]
16.3 400,000 IU versus
placebo
1 354 Mean Difference (IV, Random, 95% CI) 0.06 [0.01, 0.11]
16.4 beta-carotene: 7.8 mg
daily versus placebo
1 138 Mean Difference (IV, Random, 95% CI) 0.12 [-0.09, 0.33]
17 Breast milk retinol (mcmol/L)
at 8 - 9 months postpartum
3 Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 200,000-300,000 IU
versus placebo or no treatment
3 307 Mean Difference (IV, Random, 95% CI) 0.15 [-0.15, 0.44]
17.2 beta-carotene: 7.8 mg
daily versus placebo
1 135 Mean Difference (IV, Random, 95% CI) 0.21 [0.04, 0.38]
18 Breast milk retinol (< 1.05
mcmol/L) at 3 months
postpartum
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 200,000-300,000 IU
versus placebo or no treatment
3 373 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.19, 0.91]
18.2 beta-carotene: 7.8 mg
daily versus placebo
1 145 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.80, 1.14]
19 Breast milk retinol (< 1.05
mcmol/L) at 6 months
postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 200,000-300,000 IU
versus placebo
2 275 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.23, 1.90]
19.2 beta-carotene: 7.8 mg
daily versus placebo
1 138 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.67, 1.06]
43Vitamin A supplementation for postpartum women (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
20 Breast milk retinol (< 1.05
mcmol/L) at 8-9 months
postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 200,000-300,000 IU
versus placebo
2 257 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.48, 1.35]
20.2 beta-carotene: 7.8mg
daily versus placebo
1 135 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.63, 0.98]
21 Breast milk retinol (< 0.28
mcmol/g of fat) at 3 months
postpartum
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21.1 200,000 IU versus
placebo
1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.63, 1.03]
21.2 beta-carotene: 7.8mg
daily versus placebo
1 145 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.82, 1.23]
22 Breast milk retinol (< 0.28
mcmol/g of fat) at 6 months
postpartum
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22.1 200,000 IU versus
placebo
2 813 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.71, 0.99]
22.2 beta-carotene: 7.8mg
daily versus placebo
1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.71, 1.07]
23 Breast milk retinol (< 0.28
mcmol/g of fat) at 9 months
postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
23.1 200,000 IU versus
placebo
2 699 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.74, 1.02]
23.2 beta-carotene: 7.8 mg
daily versus placebo
1 134 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.62, 0.95]
24 Maternal abnormal
conjunctival impression
cytology 3 months postpartum
1 148 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.55, 1.80]
24.1 300,000 IU versus
placebo
1 148 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.55, 1.80]
25 Maternal abnormal
conjunctival impression
cytology 6 months postpartum
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
25.1 300,000 IU versus
placebo
1 142 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.27, 1.17]
26 Infant mortality 4 6170 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.84, 1.57]
26.1 deaths to 14 weeks:
400,000 IU versus placebo
1 564 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.57, 1.74]
26.2 deaths to 12 months:
300,000 IU versus placebo
1 598 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.34, 2.24]
26.3 death to 6 months:
200,000 IU versus placebo
1 407 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [0.26, 9.10]
26.4 deaths to 12 months:
400,000 IU versus placebo
1 4601 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.83, 1.98]
27 Infant diarrhoea (one or more
episodes) to 12 months
1 456 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.98, 1.06]
27.1 300,000 IU versus
placebo
1 456 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.98, 1.06]
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28 Infant diarrhoea episodes and
duration
Other data No numeric data
28.1 200,000 IU versus no
treatment
Other data No numeric data
29 Infant gastroenteritis to 3
months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
29.1 200,000 IU versus no
treatment
1 84 Risk Ratio (M-H, Fixed, 95% CI) 8.44 [0.45, 158.40]
30 Infant acute respiratory
infection (one or more
episodes) to 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
30.1 300,000 IU versus
placebo
1 456 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.96, 1.03]
31 Infant upper respiratory tract
infection to 3 months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
31.1 200,000 IU versus
treatment
1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.22, 3.81]
32 Infant acute respiratory tract
infection episodes and duration
Other data No numeric data
32.1 200,000 IU versus no
treatment
Other data No numeric data
33 Infant febrile illness episodes Other data No numeric data
33.1 200,000 IU versus no
treatment
Other data No numeric data
34 Infant adverse effects of
supplementation
2 9622 Risk Ratio (M-H, Random, 95% CI) 2.22 [1.01, 4.86]
34.1 Bulging fontanelle:
200,000 IU versus placebo
1 9178 Risk Ratio (M-H, Random, 95% CI) 2.41 [0.85, 6.83]
34.2 Bulging fontanelle:
400,000 IU versus placebo
1 444 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.61, 6.55]
35 Infant serum retinol (µmol/L)
at 2 - 3.5 months postpartum
3 Mean Difference (IV, Random, 95% CI) Subtotals only
35.1 200,000-400,000 IU
versus no treatment
3 320 Mean Difference (IV, Random, 95% CI) 0.12 [-0.08, 0.33]
35.2 200,000 IU versus
placebo or no treatment
2 156 Mean Difference (IV, Random, 95% CI) 0.19 [-0.04, 0.42]
35.3 400,000 IU versus
placebo
1 164 Mean Difference (IV, Random, 95% CI) 0.02 [-0.03, 0.07]
36 Infant serum retinol (µmol/L)
at 5 - 6 months postpartum
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
36.1 200,000-400,000 IU
versus placebo
4 465 Mean Difference (IV, Fixed, 95% CI) 0.04 [0.00, 0.09]
36.2 200,000-300,000 IU
versus placebo
3 324 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.01, 0.09]
36.3 beta-carotene: 7.8 mg
daily versus placebo
1 139 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.04, 0.10]
36.4 400,000 IU versus
placebo
1 141 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.02, 0.14]
37 Infant low hepatic vitamin A
stores 1.5 months postpartum
(MRDR ≥ 0.06)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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37.1 200,000 IU versus
placebo
1 600 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [1.02, 1.21]
38 Infant low hepatic vitamin
A stores at 5 - 6.5 months
postpartum
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
38.1 200,000-400,000 IU
versus placebo
3 459 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.79, 1.15]
38.2 200,000-300,000 IU
versus placebo
2 270 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.26, 1.84]
38.3 400,000 IU versus
placebo
1 189 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.90, 1.22]
38.4 beta-carotene: 7.8 mg
daily versus placebo
1 139 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.80, 1.02]
Comparison 2. Supplement (vitamin A as retinyl) high dose versus low dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Infant mortality 1 220 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.37, 10.70]
1.1 400,000 IU versus
200,000 IU
1 220 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.37, 10.70]
2 Maternal serum retinol ( mol/L) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 400,000 IU versus
200,000 IU at 2 months
postpartum
1 193 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.10, 0.14]
2.2 400,000 IU versus
200,000 IU at 3 months
postpartum
1 190 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.28, 0.16]
2.3 400,000 IU versus
200,000 IU at 6 months
postpartum
2 812 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.14, 0.13]
2.4 400,000 IU versus
200,000 IU at 9 months
postpartum
1 602 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.26, 0.08]
3 Breast milk retinol (< 1.05
mol/L)
1 382 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.69, 1.36]
3.1 400,000 IU versus
200,000 IU at 3 months
postpartum
1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.72, 2.17]
3.2 400,000 IU versus
200,000 IU at 6 months
postpartum
1 192 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.53, 1.25]
4 Infant serum retinol ( mol/L )
at 2 months postpartum
1 134 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.05, 0.09]
4.1 400,000 IU versus
200,000 IU
1 134 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.05, 0.09]
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Analysis 1.1. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 1 Maternal mortality to six months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 1 Maternal mortality to six months
Study or subgroup Vitamin A Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 400,000 IU versus placebo
Ayah 2007 2/282 4/282 100.0 % 0.50 [ 0.09, 2.71 ]
Total (95% CI) 282 282 100.0 % 0.50 [ 0.09, 2.71 ]
Total events: 2 (Vitamin A), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours supplement Favours placebo
Analysis 1.2. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 2 Maternal fever at 3 months postpartum.
Maternal fever at 3 months postpartum
Study Outcome Supplement Control P value
200,000 IU versus no treatment
Roy 1997 Number of cumulative
episodes;
(cumulative duration of ill-
ness in days)
10 (30);
n = 25
10 (28);
n = 25
Report states no significant difference
Analysis 1.3. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 3 Maternal respiratory tract infection at 3 months postpartum.
Maternal respiratory tract infection at 3 months postpartum
Study Outcome Supplement Control P value
200,000 IU versus no treatment
Roy 1997 Number of cumulative
episodes;
(cumulative duration of ill-
23 (82);
n = 25
25 (125);
n = 25
Report states no significant difference
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Maternal respiratory tract infection at 3 months postpartum (Continued)
ness in days)
Roy 1997
Analysis 1.4. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 4 Maternal diarrhoea at 3 months postpartum.
Maternal diarrhoea at 3 months postpartum
Study Outcome Vitamin A Control P value
200,000 IU versus no treatment
Roy 1997 Number of cumulative
episodes;
(cumulative duration of ill-
ness in days)
10 (27);
n = 25
2 (15);
n = 25
Report states no significant difference
Analysis 1.5. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 5 Maternal adverse effects of supplementation.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 5 Maternal adverse effects of supplementation
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 32/396 26/390 100.0 % 1.21 [ 0.74, 1.99 ]
Subtotal (95% CI) 396 390 100.0 % 1.21 [ 0.74, 1.99 ]
Total events: 32 (Supplement), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
2 Blurred vision within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 5/396 3/390 100.0 % 1.64 [ 0.39, 6.82 ]
Subtotal (95% CI) 396 390 100.0 % 1.64 [ 0.39, 6.82 ]
Total events: 5 (Supplement), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
0.05 0.2 1 5 20
Favours supplement Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 Drowsiness within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 17/396 8/390 100.0 % 2.09 [ 0.91, 4.79 ]
Subtotal (95% CI) 396 390 100.0 % 2.09 [ 0.91, 4.79 ]
Total events: 17 (Supplement), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
4 Nausea within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 7/396 5/390 100.0 % 1.38 [ 0.44, 4.31 ]
Subtotal (95% CI) 396 390 100.0 % 1.38 [ 0.44, 4.31 ]
Total events: 7 (Supplement), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
5 Vomiting within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 1/396 3/390 100.0 % 0.33 [ 0.03, 3.14 ]
Subtotal (95% CI) 396 390 100.0 % 0.33 [ 0.03, 3.14 ]
Total events: 1 (Supplement), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
6 Poor appetite within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 9/396 4/390 100.0 % 2.22 [ 0.69, 7.14 ]
Subtotal (95% CI) 396 390 100.0 % 2.22 [ 0.69, 7.14 ]
Total events: 9 (Supplement), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
7 Abdominal pain within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 82/396 63/390 100.0 % 1.28 [ 0.95, 1.73 ]
Subtotal (95% CI) 396 390 100.0 % 1.28 [ 0.95, 1.73 ]
Total events: 82 (Supplement), 63 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
0.05 0.2 1 5 20
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Analysis 1.6. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 6 Maternal serum retinol (µmol/L) at 1.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 6 Maternal serum retinol ( mol/L) at 1.5 months postpartum
Study or subgroup Vitamin A Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HIV negative women: 400,000 IU versus placebo
ZVITAMBO Study Group 128 1.74 (0.45) 132 1.65 (0.44) 100.0 % 0.09 [ -0.02, 0.20 ]
Total (95% CI) 128 132 100.0 % 0.09 [ -0.02, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours supplement Favours placebo
50Vitamin A supplementation for postpartum women (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 7 Maternal serum retinol (mcmol/L) at 3 - 3.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 7 Maternal serum retinol (mcmol/L) at 3 - 3.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000-400,000 IU versus placebo or no treatment
Ayah 2007 205 1.05 (0.22) 197 1.01 (0.29) 47.8 % 0.04 [ -0.01, 0.09 ]
RETIBETA Project 34 1.45 (0.47) 35 1.33 (0.42) 15.0 % 0.12 [ -0.09, 0.33 ]
Roy 1997 25 1.59 (0.39) 25 1.33 (0.39) 14.4 % 0.26 [ 0.04, 0.48 ]
Stoltzfus 1993a 70 1.39 (0.49) 69 1.24 (0.43) 22.8 % 0.15 [ 0.00, 0.30 ]
Subtotal (95% CI) 334 326 100.0 % 0.11 [ 0.01, 0.20 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.51, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 2.23 (P = 0.026)
2 200,000-300,000 IU versus placebo or no treatment
RETIBETA Project 34 1.45 (0.47) 35 1.33 (0.42) 26.1 % 0.12 [ -0.09, 0.33 ]
Roy 1997 25 1.59 (0.39) 25 1.33 (0.39) 24.7 % 0.26 [ 0.04, 0.48 ]
Stoltzfus 1993a 70 1.39 (0.49) 69 1.24 (0.43) 49.2 % 0.15 [ 0.00, 0.30 ]
Subtotal (95% CI) 129 129 100.0 % 0.17 [ 0.06, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.09 (P = 0.0020)
3 400,000 IU versus placebo
Ayah 2007 205 1.05 (0.22) 197 1.01 (0.29) 100.0 % 0.04 [ -0.01, 0.09 ]
Subtotal (95% CI) 205 197 100.0 % 0.04 [ -0.01, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
4 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 36 1.43 (0.43) 35 1.33 (0.42) 100.0 % 0.10 [ -0.10, 0.30 ]
Subtotal (95% CI) 36 35 100.0 % 0.10 [ -0.10, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
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Analysis 1.8. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 8 Maternal serum retinol (mcmol/L) at 6 - 6.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 8 Maternal serum retinol (mcmol/L) at 6 - 6.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000-400,000 IU versus placebo or no treatment
Ayah 2007 148 0.96 (0.25) 143 0.98 (0.24) 40.5 % -0.02 [ -0.08, 0.04 ]
RETIBETA Project 35 1.47 (0.38) 36 1.52 (0.56) 17.0 % -0.05 [ -0.27, 0.17 ]
Roy 1997 25 1.54 (0.65) 25 1.36 (0.34) 12.0 % 0.18 [ -0.11, 0.47 ]
Stoltzfus 1993a 67 1.23 (0.34) 72 1.08 (0.37) 30.6 % 0.15 [ 0.03, 0.27 ]
Subtotal (95% CI) 275 276 100.0 % 0.05 [ -0.07, 0.17 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.10, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 0.86 (P = 0.39)
2 200,000-300,000 IU versus placebo or no treatment
RETIBETA Project 35 1.47 (0.38) 36 1.52 (0.56) 25.3 % -0.05 [ -0.27, 0.17 ]
Roy 1997 25 1.54 (0.65) 25 1.36 (0.34) 16.5 % 0.18 [ -0.11, 0.47 ]
Stoltzfus 1993a 67 1.23 (0.34) 72 1.08 (0.37) 58.2 % 0.15 [ 0.03, 0.27 ]
Subtotal (95% CI) 127 133 100.0 % 0.10 [ -0.02, 0.23 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.65, df = 2 (P = 0.27); I2 =25%
Test for overall effect: Z = 1.63 (P = 0.10)
3 400,000 IU versus placebo
Ayah 2007 148 0.96 (0.25) 143 0.98 (0.24) 100.0 % -0.02 [ -0.08, 0.04 ]
Subtotal (95% CI) 148 143 100.0 % -0.02 [ -0.08, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
4 beta-carotene: 7.8mg daily versus placebo
RETIBETA Project 32 1.57 (0.59) 36 1.52 (0.56) 100.0 % 0.05 [ -0.22, 0.32 ]
Subtotal (95% CI) 32 36 100.0 % 0.05 [ -0.22, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
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Analysis 1.9. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 9 Maternal serum retinol (mcmol/L) at 9 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 9 Maternal serum retinol (mcmol/L) at 9 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 200,000-300,000 IU versus placebo or no treatment
RETIBETA Project 32 1.47 (0.46) 31 1.36 (0.45) 46.2 % 0.11 [ -0.11, 0.33 ]
Roy 1997 25 1.29 (0.39) 25 1.35 (0.36) 53.8 % -0.06 [ -0.27, 0.15 ]
Subtotal (95% CI) 57 56 100.0 % 0.02 [ -0.13, 0.17 ]
Heterogeneity: Chi2 = 1.18, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 0.24 (P = 0.81)
2 beta-carotene: 7.8mg daily versus placebo
RETIBETA Project 35 1.55 (0.47) 31 1.36 (0.45) 100.0 % 0.19 [ -0.03, 0.41 ]
Subtotal (95% CI) 35 31 100.0 % 0.19 [ -0.03, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
Test for subgroup differences: Chi2 = 1.56, df = 1 (P = 0.21), I2 =36%
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Analysis 1.10. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 10 Maternal low hepatic vitamin A stores 3 months postpartum
(MRDR ≥ 0.06).
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 10 Maternal low hepatic vitamin A stores 3 months postpartum (MRDR ≥ 0.06)
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus placebo
RETIBETA Project 6/34 19/35 100.0 % 0.33 [ 0.15, 0.71 ]
Subtotal (95% CI) 34 35 100.0 % 0.33 [ 0.15, 0.71 ]
Total events: 6 (Supplement), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
2 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 15/36 19/35 100.0 % 0.77 [ 0.47, 1.26 ]
Subtotal (95% CI) 36 35 100.0 % 0.77 [ 0.47, 1.26 ]
Total events: 15 (Supplement), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
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Analysis 1.11. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 11 Maternal low hepatic vitamin A stores 5 - 6 months postpartum
(MRDR ≥ 0.06).
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 11 Maternal low hepatic vitamin A stores 5 - 6 months postpartum (MRDR ≥ 0.06)
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus placebo
RETIBETA Project 11/35 12/36 100.0 % 0.94 [ 0.48, 1.85 ]
Subtotal (95% CI) 35 36 100.0 % 0.94 [ 0.48, 1.85 ]
Total events: 11 (Supplement), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
2 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 6/32 12/36 100.0 % 0.56 [ 0.24, 1.32 ]
Subtotal (95% CI) 32 36 100.0 % 0.56 [ 0.24, 1.32 ]
Total events: 6 (Supplement), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 1.12. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 12 Maternal low hepatic vitamin A stores 9 months postpartum
(MRDR ≥ 0.06).
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 12 Maternal low hepatic vitamin A stores 9 months postpartum (MRDR ≥ 0.06)
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus placebo
RETIBETA Project 9/32 13/31 100.0 % 0.67 [ 0.34, 1.34 ]
Subtotal (95% CI) 32 31 100.0 % 0.67 [ 0.34, 1.34 ]
Total events: 9 (Supplement), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
2 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 9/35 13/31 100.0 % 0.61 [ 0.30, 1.23 ]
Subtotal (95% CI) 35 31 100.0 % 0.61 [ 0.30, 1.23 ]
Total events: 9 (Supplement), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
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Analysis 1.13. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 13 Maternal low hepatic vitamin A stores 3 months postpartum
(RDR > 20%).
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 13 Maternal low hepatic vitamin A stores 3 months postpartum (RDR > 20%)
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Stoltzfus 1993a 7/70 6/69 100.0 % 1.15 [ 0.41, 3.25 ]
Total (95% CI) 70 69 100.0 % 1.15 [ 0.41, 3.25 ]
Total events: 7 (Supplement), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
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Analysis 1.14. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 14 Maternal low hepatic vitamin A stores 6 months postpartum
(RDR > 20%).
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 14 Maternal low hepatic vitamin A stores 6 months postpartum (RDR > 20%)
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Stoltzfus 1993a 2/67 1/72 100.0 % 2.15 [ 0.20, 23.16 ]
Total (95% CI) 67 72 100.0 % 2.15 [ 0.20, 23.16 ]
Total events: 2 (Supplement), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 1.15. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 15 Breast milk retinol (mcmol/L) at 3 - 3.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 15 Breast milk retinol (mcmol/L) at 3 - 3.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000-400,000 IU versus placebo no treatment
Ayah 2007 221 0.52 (0.23) 201 0.44 (0.28) 36.0 % 0.08 [ 0.03, 0.13 ]
RETIBETA Project 69 1.2 (1) 72 0.83 (0.43) 15.0 % 0.37 [ 0.11, 0.63 ]
Roy 1997 25 1.34 (0.53) 25 1.12 (0.51) 12.9 % 0.22 [ -0.07, 0.51 ]
Stoltzfus 1993a 57 2.45 (1.23) 60 1.82 (1.28) 6.5 % 0.63 [ 0.18, 1.08 ]
Vinutha 2000 36 1.09 (0.26) 46 0.92 (0.24) 29.7 % 0.17 [ 0.06, 0.28 ]
Subtotal (95% CI) 408 404 100.0 % 0.20 [ 0.08, 0.33 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 12.12, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 3.14 (P = 0.0017)
2 200,000-300,000 IU versus placebo no treatment
RETIBETA Project 69 1.2 (1) 72 0.83 (0.43) 23.4 % 0.37 [ 0.11, 0.63 ]
Roy 1997 25 1.34 (0.53) 25 1.12 (0.51) 20.2 % 0.22 [ -0.07, 0.51 ]
Stoltzfus 1993a 57 2.45 (1.23) 60 1.82 (1.28) 10.2 % 0.63 [ 0.18, 1.08 ]
Vinutha 2000 36 1.09 (0.26) 46 0.92 (0.24) 46.2 % 0.17 [ 0.06, 0.28 ]
Subtotal (95% CI) 187 203 100.0 % 0.27 [ 0.11, 0.43 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.24, df = 3 (P = 0.16); I2 =43%
Test for overall effect: Z = 3.36 (P = 0.00077)
3 400,000 IU versus placebo
Ayah 2007 221 0.52 (0.23) 201 0.44 (0.28) 100.0 % 0.08 [ 0.03, 0.13 ]
Subtotal (95% CI) 221 201 100.0 % 0.08 [ 0.03, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
4 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 73 0.85 (0.55) 72 0.83 (0.43) 100.0 % 0.02 [ -0.14, 0.18 ]
Subtotal (95% CI) 73 72 100.0 % 0.02 [ -0.14, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
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Analysis 1.16. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 16 Breast milk retinol (mcmol/L) at 6 - 6.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 16 Breast milk retinol (mcmol/L) at 6 - 6.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000-400,000 IU versus placebo or no treatment
Ayah 2007 184 0.5 (0.21) 170 0.44 (0.27) 33.3 % 0.06 [ 0.01, 0.11 ]
RETIBETA Project 70 0.85 (0.53) 69 0.87 (0.61) 25.8 % -0.02 [ -0.21, 0.17 ]
Roy 1997 25 1.06 (0.46) 25 0.73 (0.22) 25.2 % 0.33 [ 0.13, 0.53 ]
Stoltzfus 1993a 66 2.36 (1.17) 70 1.77 (0.97) 15.7 % 0.59 [ 0.23, 0.95 ]
Subtotal (95% CI) 345 334 100.0 % 0.19 [ -0.01, 0.39 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 15.28, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 1.91 (P = 0.056)
2 200,000-300,000 IU versus placebo or no treatment
RETIBETA Project 70 0.85 (0.53) 69 0.87 (0.61) 36.5 % -0.02 [ -0.21, 0.17 ]
Roy 1997 25 1.06 (0.46) 25 0.73 (0.22) 36.0 % 0.33 [ 0.13, 0.53 ]
Stoltzfus 1993a 66 2.36 (1.17) 70 1.77 (0.97) 27.5 % 0.59 [ 0.23, 0.95 ]
Subtotal (95% CI) 161 164 100.0 % 0.27 [ -0.05, 0.60 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 11.22, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 1.65 (P = 0.099)
3 400,000 IU versus placebo
Ayah 2007 184 0.5 (0.21) 170 0.44 (0.27) 100.0 % 0.06 [ 0.01, 0.11 ]
Subtotal (95% CI) 184 170 100.0 % 0.06 [ 0.01, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
4 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 69 0.99 (0.62) 69 0.87 (0.61) 100.0 % 0.12 [ -0.09, 0.33 ]
Subtotal (95% CI) 69 69 100.0 % 0.12 [ -0.09, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
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Analysis 1.17. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 17 Breast milk retinol (mcmol/L) at 8 - 9 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 17 Breast milk retinol (mcmol/L) at 8 - 9 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000-300,000 IU versus placebo or no treatment
RETIBETA Project 64 0.91 (0.68) 65 0.79 (0.44) 43.2 % 0.12 [ -0.08, 0.32 ]
Roy 1997 25 0.94 (0.44) 25 1.09 (0.87) 28.3 % -0.15 [ -0.53, 0.23 ]
Stoltzfus 1993a 63 2.04 (1.19) 65 1.56 (0.99) 28.5 % 0.48 [ 0.10, 0.86 ]
Subtotal (95% CI) 152 155 100.0 % 0.15 [ -0.15, 0.44 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 5.33, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 0.97 (P = 0.33)
2 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 70 1 (0.58) 65 0.79 (0.44) 100.0 % 0.21 [ 0.04, 0.38 ]
Subtotal (95% CI) 70 65 100.0 % 0.21 [ 0.04, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
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Analysis 1.18. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 18 Breast milk retinol (< 1.05 mcmol/L) at 3 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 18 Breast milk retinol (< 1.05 mcmol/L) at 3 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000-300,000 IU versus placebo or no treatment
RETIBETA Project 39/69 57/72 38.6 % 0.71 [ 0.56, 0.91 ]
Stoltzfus 1993a 6/57 19/60 27.4 % 0.33 [ 0.14, 0.77 ]
Vinutha 2000 13/69 32/46 34.0 % 0.27 [ 0.16, 0.46 ]
Subtotal (95% CI) 195 178 100.0 % 0.42 [ 0.19, 0.91 ]
Total events: 58 (Supplement), 108 (Placebo)
Heterogeneity: Tau2 = 0.40; Chi2 = 14.68, df = 2 (P = 0.00065); I2 =86%
Test for overall effect: Z = 2.19 (P = 0.029)
2 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 55/73 57/72 100.0 % 0.95 [ 0.80, 1.14 ]
Subtotal (95% CI) 73 72 100.0 % 0.95 [ 0.80, 1.14 ]
Total events: 55 (Supplement), 57 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
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Analysis 1.19. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 19 Breast milk retinol (< 1.05 mcmol/L) at 6 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 19 Breast milk retinol (< 1.05 mcmol/L) at 6 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000-300,000 IU versus placebo
RETIBETA Project 51/70 51/69 57.7 % 0.99 [ 0.81, 1.20 ]
Stoltzfus 1993a 6/66 17/70 42.3 % 0.37 [ 0.16, 0.89 ]
Subtotal (95% CI) 136 139 100.0 % 0.65 [ 0.23, 1.90 ]
Total events: 57 (Supplement), 68 (Placebo)
Heterogeneity: Tau2 = 0.50; Chi2 = 5.86, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.78 (P = 0.44)
2 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 43/69 51/69 100.0 % 0.84 [ 0.67, 1.06 ]
Subtotal (95% CI) 69 69 100.0 % 0.84 [ 0.67, 1.06 ]
Total events: 43 (Supplement), 51 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 1.20. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 20 Breast milk retinol (< 1.05 mcmol/L) at 8-9 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 20 Breast milk retinol (< 1.05 mcmol/L) at 8-9 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000-300,000 IU versus placebo
RETIBETA Project 48/64 52/65 67.9 % 0.94 [ 0.78, 1.13 ]
Stoltzfus 1993a 10/63 18/65 32.1 % 0.57 [ 0.29, 1.14 ]
Subtotal (95% CI) 127 130 100.0 % 0.80 [ 0.48, 1.35 ]
Total events: 58 (Supplement), 70 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 2.42, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.84 (P = 0.40)
2 beta-carotene: 7.8mg daily versus placebo
RETIBETA Project 44/70 52/65 100.0 % 0.79 [ 0.63, 0.98 ]
Subtotal (95% CI) 70 65 100.0 % 0.79 [ 0.63, 0.98 ]
Total events: 44 (Supplement), 52 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.030)
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Analysis 1.21. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 21 Breast milk retinol (< 0.28 mcmol/g of fat) at 3 months
postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 21 Breast milk retinol (< 0.28 mcmol/g of fat) at 3 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus placebo
RETIBETA Project 40/69 52/72 100.0 % 0.80 [ 0.63, 1.03 ]
Subtotal (95% CI) 69 72 100.0 % 0.80 [ 0.63, 1.03 ]
Total events: 40 (Supplement), 52 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
2 beta-carotene: 7.8mg daily versus placebo
RETIBETA Project 53/73 52/72 100.0 % 1.01 [ 0.82, 1.23 ]
Subtotal (95% CI) 73 72 100.0 % 1.01 [ 0.82, 1.23 ]
Total events: 53 (Supplement), 52 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 1.22. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 22 Breast milk retinol (< 0.28 mcmol/g of fat) at 6 months
postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 22 Breast milk retinol (< 0.28 mcmol/g of fat) at 6 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus placebo
RETIBETA Project 48/70 54/69 33.1 % 0.88 [ 0.72, 1.07 ]
WHO/CHD IVASSG 91/340 109/334 66.9 % 0.82 [ 0.65, 1.04 ]
Subtotal (95% CI) 410 403 100.0 % 0.84 [ 0.71, 0.99 ]
Total events: 139 (Supplement), 163 (Placebo)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
2 beta-carotene: 7.8mg daily versus placebo
RETIBETA Project 47/69 54/69 100.0 % 0.87 [ 0.71, 1.07 ]
Subtotal (95% CI) 69 69 100.0 % 0.87 [ 0.71, 1.07 ]
Total events: 47 (Supplement), 54 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 1.23. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 23 Breast milk retinol (< 0.28 mcmol/g of fat) at 9 months
postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 23 Breast milk retinol (< 0.28 mcmol/g of fat) at 9 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 IU versus placebo
RETIBETA Project 43/64 53/65 61.5 % 0.82 [ 0.67, 1.01 ]
WHO/CHD IVASSG 76/276 86/294 38.5 % 0.94 [ 0.72, 1.22 ]
Subtotal (95% CI) 340 359 100.0 % 0.87 [ 0.74, 1.02 ]
Total events: 119 (Supplement), 139 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
2 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 43/69 53/65 100.0 % 0.76 [ 0.62, 0.95 ]
Subtotal (95% CI) 69 65 100.0 % 0.76 [ 0.62, 0.95 ]
Total events: 43 (Supplement), 53 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
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Analysis 1.24. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 24 Maternal abnormal conjunctival impression cytology 3 months
postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 24 Maternal abnormal conjunctival impression cytology 3 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Stoltzfus 1993a 17/74 17/74 100.0 % 1.00 [ 0.55, 1.80 ]
Total (95% CI) 74 74 100.0 % 1.00 [ 0.55, 1.80 ]
Total events: 17 (Supplement), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 1.25. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 25 Maternal abnormal conjunctival impression cytology 6 months
postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 25 Maternal abnormal conjunctival impression cytology 6 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Stoltzfus 1993a 9/69 17/73 100.0 % 0.56 [ 0.27, 1.17 ]
Subtotal (95% CI) 69 73 100.0 % 0.56 [ 0.27, 1.17 ]
Total events: 9 (Supplement), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 1.26. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 26 Infant mortality.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 26 Infant mortality
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 deaths to 14 weeks: 400,000 IU versus placebo
Ayah 2007 23/282 23/282 32.9 % 1.00 [ 0.57, 1.74 ]
Subtotal (95% CI) 282 282 32.9 % 1.00 [ 0.57, 1.74 ]
Total events: 23 (Supplement), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 deaths to 12 months: 300,000 IU versus placebo
Venkatarao 1996 8/301 9/297 12.9 % 0.88 [ 0.34, 2.24 ]
Subtotal (95% CI) 301 297 12.9 % 0.88 [ 0.34, 2.24 ]
Total events: 8 (Supplement), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
3 death to 6 months: 200,000 IU versus placebo
Newton 2005 3/201 2/206 2.8 % 1.54 [ 0.26, 9.10 ]
Subtotal (95% CI) 201 206 2.8 % 1.54 [ 0.26, 9.10 ]
Total events: 3 (Supplement), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
4 deaths to 12 months: 400,000 IU versus placebo
ZVITAMBO Study Group 46/2296 36/2305 51.4 % 1.28 [ 0.83, 1.98 ]
Subtotal (95% CI) 2296 2305 51.4 % 1.28 [ 0.83, 1.98 ]
Total events: 46 (Supplement), 36 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 3080 3090 100.0 % 1.14 [ 0.84, 1.57 ]
Total events: 80 (Supplement), 70 (Placebo)
Heterogeneity: Chi2 = 0.91, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
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Analysis 1.27. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 27 Infant diarrhoea (one or more episodes) to 12 months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 27 Infant diarrhoea (one or more episodes) to 12 months
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Venkatarao 1996 221/228 216/228 100.0 % 1.02 [ 0.98, 1.06 ]
Total (95% CI) 228 228 100.0 % 1.02 [ 0.98, 1.06 ]
Total events: 221 (Supplement), 216 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 28 Infant diarrhoea episodes and duration.
Infant diarrhoea episodes and duration
Study Outcome Supplement No treatment Significance
200,000 IU versus no treatment
Roy 1997 Diarrhoea episodes RR/OR?? 0.12 (95% CI 0.09
to 0.15)
0.11 (95% CI 0.08 to 0.14) P = 0.59
Roy 1997 Diarrhoea duration 0.74 (95% CI 0.53 to 0.95) 0.71 (95% CI 0.50 to 0.92) P = 0.78
Roy 1997 Child-weeks 515 522
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Analysis 1.29. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 29 Infant gastroenteritis to 3 months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 29 Infant gastroenteritis to 3 months
Study or subgroup Supplement Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus no treatment
Vinutha 2000 3/38 0/46 100.0 % 8.44 [ 0.45, 158.40 ]
Subtotal (95% CI) 38 46 100.0 % 8.44 [ 0.45, 158.40 ]
Total events: 3 (Supplement), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
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Analysis 1.30. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 30 Infant acute respiratory infection (one or more episodes) to 12
months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 30 Infant acute respiratory infection (one or more episodes) to 12 months
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Venkatarao 1996 218/228 219/228 100.0 % 1.00 [ 0.96, 1.03 ]
Subtotal (95% CI) 228 228 100.0 % 1.00 [ 0.96, 1.03 ]
Total events: 218 (Supplement), 219 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.81)
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Analysis 1.31. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 31 Infant upper respiratory tract infection to 3 months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 31 Infant upper respiratory tract infection to 3 months
Study or subgroup Supplement Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus treatment
Vinutha 2000 3/38 4/46 100.0 % 0.91 [ 0.22, 3.81 ]
Subtotal (95% CI) 38 46 100.0 % 0.91 [ 0.22, 3.81 ]
Total events: 3 (Supplement), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
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Analysis 1.32. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 32 Infant acute respiratory tract infection episodes and duration.
Infant acute respiratory tract infection episodes and duration
Study Outcome / Details Vitamin A Control Significance
200,000 IU versus no treatment
Roy 1997 Acute respiratory tract infec-
tion episodes
(mean episodes per child-
week of observation)
0.42 (95% CI 0.38 to 0.46) 0.45 (95% CI 0.41 to 0.49) P = 0.51
Roy 1997 Acute respiratory tract infec-
tion duration
(duration (days) per child-
week of observation)
3.1 (95% CI 2.7 to 3.5) 3.7 (95% CI 3.25 to 4.15) P = 0.03
Roy 1997 Child-weeks 515 522
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Analysis 1.33. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 33 Infant febrile illness episodes.
Infant febrile illness episodes
Study Outcome / Details Vitamin A Control Significance
200,000 IU versus no treatment
Roy 1997 Febrile illness episodes
(mean episodes per child-
week of observation)
0.1 (95% CI 0.09 to 0.11) 0.3 (95% CI 0.27 to 0.30) P < 0.002
Roy 1997 Child-weeks 515 522
Analysis 1.34. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 34 Infant adverse effects of supplementation.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 34 Infant adverse effects of supplementation
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bulging fontanelle: 200,000 IU versus placebo
WHO/CHD IVASSG 12/4582 5/4596 56.4 % 2.41 [ 0.85, 6.83 ]
Subtotal (95% CI) 4582 4596 56.4 % 2.41 [ 0.85, 6.83 ]
Total events: 12 (Supplement), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
2 Bulging fontanelle: 400,000 IU versus placebo
Ayah 2007 8/222 4/222 43.6 % 2.00 [ 0.61, 6.55 ]
Subtotal (95% CI) 222 222 43.6 % 2.00 [ 0.61, 6.55 ]
Total events: 8 (Supplement), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 4804 4818 100.0 % 2.22 [ 1.01, 4.86 ]
Total events: 20 (Supplement), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
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Analysis 1.35. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 35 Infant serum retinol (µmol/L) at 2 - 3.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 35 Infant serum retinol ( mol/L) at 2 - 3.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000-400,000 IU versus no treatment
Ayah 2007 78 0.92 (0.18) 86 0.9 (0.14) 37.9 % 0.02 [ -0.03, 0.07 ]
Bhaskaram 2000 49 0.94 (0.55) 40 0.89 (0.51) 26.6 % 0.05 [ -0.17, 0.27 ]
Vinutha 2000 38 1.06 (0.21) 29 0.77 (0.2) 35.5 % 0.29 [ 0.19, 0.39 ]
Subtotal (95% CI) 165 155 100.0 % 0.12 [ -0.08, 0.33 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 22.95, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 1.19 (P = 0.23)
2 200,000 IU versus placebo or no treatment
Bhaskaram 2000 49 0.94 (0.55) 40 0.89 (0.51) 41.2 % 0.05 [ -0.17, 0.27 ]
Vinutha 2000 38 1.06 (0.21) 29 0.77 (0.2) 58.8 % 0.29 [ 0.19, 0.39 ]
Subtotal (95% CI) 87 69 100.0 % 0.19 [ -0.04, 0.42 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.79, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 1.62 (P = 0.11)
3 400,000 IU versus placebo
Ayah 2007 78 0.92 (0.18) 86 0.9 (0.14) 100.0 % 0.02 [ -0.03, 0.07 ]
Subtotal (95% CI) 78 86 100.0 % 0.02 [ -0.03, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
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Analysis 1.36. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 36 Infant serum retinol (µmol/L) at 5 - 6 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 36 Infant serum retinol ( mol/L) at 5 - 6 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 200,000-400,000 IU versus placebo
Ayah 2007 75 1.08 (0.31) 66 1.02 (0.17) 28.1 % 0.06 [ -0.02, 0.14 ]
Bhaskaram 2000 22 0.81 (0.35) 25 0.88 (0.31) 5.1 % -0.07 [ -0.26, 0.12 ]
RETIBETA Project 69 0.84 (0.23) 70 0.77 (0.21) 34.6 % 0.07 [ 0.00, 0.14 ]
Stoltzfus 1993a 68 0.67 (0.19) 70 0.65 (0.26) 32.2 % 0.02 [ -0.06, 0.10 ]
Subtotal (95% CI) 234 231 100.0 % 0.04 [ 0.00, 0.09 ]
Heterogeneity: Chi2 = 2.40, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
2 200,000-300,000 IU versus placebo
Bhaskaram 2000 22 0.81 (0.35) 25 0.88 (0.31) 7.1 % -0.07 [ -0.26, 0.12 ]
RETIBETA Project 69 0.84 (0.23) 70 0.77 (0.21) 48.0 % 0.07 [ 0.00, 0.14 ]
Stoltzfus 1993a 68 0.67 (0.19) 70 0.65 (0.26) 44.8 % 0.02 [ -0.06, 0.10 ]
Subtotal (95% CI) 159 165 100.0 % 0.04 [ -0.01, 0.09 ]
Heterogeneity: Chi2 = 2.19, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 1.45 (P = 0.15)
3 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 69 0.8 (0.22) 70 0.77 (0.21) 100.0 % 0.03 [ -0.04, 0.10 ]
Subtotal (95% CI) 69 70 100.0 % 0.03 [ -0.04, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
4 400,000 IU versus placebo
Ayah 2007 75 1.08 (0.31) 66 1.02 (0.17) 100.0 % 0.06 [ -0.02, 0.14 ]
Subtotal (95% CI) 75 66 100.0 % 0.06 [ -0.02, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 1.37. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 37 Infant low hepatic vitamin A stores 1.5 months postpartum
(MRDR ≥ 0.06).
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 37 Infant low hepatic vitamin A stores 1.5 months postpartum (MRDR ≥ 0.06)
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus placebo
WHO/CHD IVASSG 238/291 227/309 100.0 % 1.11 [ 1.02, 1.21 ]
Subtotal (95% CI) 291 309 100.0 % 1.11 [ 1.02, 1.21 ]
Total events: 238 (Supplement), 227 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
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Analysis 1.38. Comparison 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus
control (placebo, no treatment), Outcome 38 Infant low hepatic vitamin A stores at 5 - 6.5 months
postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water miscible or beta-carotene) versus control (placebo, no treatment)
Outcome: 38 Infant low hepatic vitamin A stores at 5 - 6.5 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000-400,000 IU versus placebo
Ayah 2007 77/96 71/93 44.3 % 1.05 [ 0.90, 1.22 ]
RETIBETA Project 60/69 65/70 51.1 % 0.94 [ 0.84, 1.05 ]
Stoltzfus 1993a 7/67 15/64 4.6 % 0.45 [ 0.19, 1.02 ]
Subtotal (95% CI) 232 227 100.0 % 0.95 [ 0.79, 1.15 ]
Total events: 144 (Supplement), 151 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.18, df = 2 (P = 0.07); I2 =61%
Test for overall effect: Z = 0.52 (P = 0.60)
2 200,000-300,000 IU versus placebo
RETIBETA Project 60/69 65/70 58.5 % 0.94 [ 0.84, 1.05 ]
Stoltzfus 1993a 7/67 15/64 41.5 % 0.45 [ 0.19, 1.02 ]
Subtotal (95% CI) 136 134 100.0 % 0.69 [ 0.26, 1.84 ]
Total events: 67 (Supplement), 80 (Placebo)
Heterogeneity: Tau2 = 0.43; Chi2 = 5.70, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.74 (P = 0.46)
3 400,000 IU versus placebo
Ayah 2007 77/96 71/93 100.0 % 1.05 [ 0.90, 1.22 ]
Subtotal (95% CI) 96 93 100.0 % 1.05 [ 0.90, 1.22 ]
Total events: 77 (Supplement), 71 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 58/69 65/70 100.0 % 0.91 [ 0.80, 1.02 ]
Subtotal (95% CI) 69 70 100.0 % 0.91 [ 0.80, 1.02 ]
Total events: 58 (Supplement), 65 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
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Analysis 2.1. Comparison 2 Supplement (vitamin A as retinyl) high dose versus low dose, Outcome 1 Infant
mortality.
Review: Vitamin A supplementation for postpartum women
Comparison: 2 Supplement (vitamin A as retinyl) high dose versus low dose
Outcome: 1 Infant mortality
Study or subgroup 400000 IU 200000 IU Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 400,000 IU versus 200,000 IU
Darboe 2007 4/110 2/110 100.0 % 2.00 [ 0.37, 10.70 ]
Total (95% CI) 110 110 100.0 % 2.00 [ 0.37, 10.70 ]
Total events: 4 (400000 IU), 2 (200000 IU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Supplement (vitamin A as retinyl) high dose versus low dose, Outcome 2
Maternal serum retinol ( mol/L).
Review: Vitamin A supplementation for postpartum women
Comparison: 2 Supplement (vitamin A as retinyl) high dose versus low dose
Outcome: 2 Maternal serum retinol ( mol/L)
Study or subgroup high dose low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 400,000 IU versus 200,000 IU at 2 months postpartum
Darboe 2007 96 1.43 (0.44) 97 1.41 (0.4) 100.0 % 0.02 [ -0.10, 0.14 ]
Subtotal (95% CI) 96 97 100.0 % 0.02 [ -0.10, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 400,000 IU versus 200,000 IU at 3 months postpartum
Darboe 2007 94 1.68 (0.79) 96 1.74 (0.78) 100.0 % -0.06 [ -0.28, 0.16 ]
Subtotal (95% CI) 94 96 100.0 % -0.06 [ -0.28, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
3 400,000 IU versus 200,000 IU at 6 months postpartum
Darboe 2007 96 1.56 (0.84) 96 1.47 (0.71) 37.8 % 0.09 [ -0.13, 0.31 ]
Idindili 2007 314 1.82 (1.09) 306 1.88 (1.09) 62.2 % -0.06 [ -0.23, 0.11 ]
Subtotal (95% CI) 410 402 100.0 % 0.00 [ -0.14, 0.13 ]
Heterogeneity: Chi2 = 1.11, df = 1 (P = 0.29); I2 =10%
Test for overall effect: Z = 0.05 (P = 0.96)
4 400,000 IU versus 200,000 IU at 9 months postpartum
Idindili 2007 305 1.86 (1.19) 297 1.95 (0.97) 100.0 % -0.09 [ -0.26, 0.08 ]
Subtotal (95% CI) 305 297 100.0 % -0.09 [ -0.26, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Chi2 = 1.24, df = 3 (P = 0.74), I2 =0.0%
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Analysis 2.3. Comparison 2 Supplement (vitamin A as retinyl) high dose versus low dose, Outcome 3 Breast
milk retinol (< 1.05 mol/L).
Review: Vitamin A supplementation for postpartum women
Comparison: 2 Supplement (vitamin A as retinyl) high dose versus low dose
Outcome: 3 Breast milk retinol (< 1.05 mol/L)
Study or subgroup high dose low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 400,000 IU versus 200,000 IU at 3 months postpartum
Darboe 2007 22/94 18/96 35.8 % 1.25 [ 0.72, 2.17 ]
Subtotal (95% CI) 94 96 35.8 % 1.25 [ 0.72, 2.17 ]
Total events: 22 (high dose), 18 (low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 400,000 IU versus 200,000 IU at 6 months postpartum
Darboe 2007 26/96 32/96 64.2 % 0.81 [ 0.53, 1.25 ]
Subtotal (95% CI) 96 96 64.2 % 0.81 [ 0.53, 1.25 ]
Total events: 26 (high dose), 32 (low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 190 192 100.0 % 0.97 [ 0.69, 1.36 ]
Total events: 48 (high dose), 50 (low dose)
Heterogeneity: Chi2 = 1.44, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 2.4. Comparison 2 Supplement (vitamin A as retinyl) high dose versus low dose, Outcome 4 Infant
serum retinol ( mol/L ) at 2 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 2 Supplement (vitamin A as retinyl) high dose versus low dose
Outcome: 4 Infant serum retinol ( mol/L ) at 2 months postpartum
Study or subgroup high dose low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 400,000 IU versus 200,000 IU
Darboe 2007 63 0.74 (0.21) 71 0.72 (0.2) 100.0 % 0.02 [ -0.05, 0.09 ]
Total (95% CI) 63 71 100.0 % 0.02 [ -0.05, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Additional search strategies
LILACS - Latin American and Caribbean Health Sciences by Bireme (1982 to July 2010)
#1: ((Pt ENSAIO CONTROLADO ALEATORIO OR Pt ENSAIO CLINICO CONTROLADO OR Mh ENSAIOS CONTRO-
LADOS ALEATORIOS OR Mh DISTRIBUICAO ALEATORIA OR Mh MÉTODO DUPLO-CEGO OR Mh MÉTODO SIM-
PLES-CEGO) AND NOT (Ct ANIMAIS AND NOT (Ct HUMANO AND Ct ANIMAIS)) OR (Pt ENSAIO CLÍNICO OR Ex
E05.318.760.535$) OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw
singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$
OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh PLACEBOS OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw
casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR (Mh PROJETOS DE PESQUISA) ANDNOT (Ct ANIMAIS ANDNOT
(Ct HUMANO AND Ct ANIMAIS)) OR (Ct ESTUDO COMPARATIVO OR Ex E05.337$ OR Mh SEGUIMENTOS OR Mh
ESTUDOS PROSPECTIVOS OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct ANIMAIS
AND NOT (Ct HUMANO AND Ct ANIMAIS))) AND NOTMh ANIMAIS [Palavras]
#2: retinol or “vitamin A” or caroten$ [Palavras]
#3: #1 AND #2
WEB OF SCIENCE by ISI (1945 to July 2010)
#1: TS=(randomised controlled trial) OR TS=(controlled clinical trial) OR TS=(randomised controlled trials) OR TS=(random allo-
cation) OR TS=(double-blind method) OR TS=(single-blind method) OR TS=(clinical trial) OR TS=(clinical trials) OR TS=(clinical
trial) OR ((TS=singl* OR TS=doubl* OR TS=trebl* OR TS=tripl*) AND (TS=mask* OR TS=blind*)) OR (TS=(latin square) OR
TS=placebo* OR TS=random* OR TS=(research design) or TS=(comparative study) OR TS=(evaluation studies) OR TS=(follow-up
studies) OR TS=(prospective studies) OR TS=(cross-over studies) OR TS=control* OR TS=prospectiv* OR TS=volunteer*)
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#2: TS=puerp* or TS=matern* or TS=lacta* or TS=breastfe* or TS=(breast fee*) or TS=breast-fee* or TS=(humanmilk) or TS=postnatal
or TS=postpart* or TS=newborn* or TS=infant* or TS=newborn
#3: TS=retinol* or TS=(vitamin A) or TS=caroten*
#4: #3 AND #2 AND #1
BIOLOGICAL ABSTRACTS (1998 to July 2010), HUMANNUTRITION (1982 to October 2007), FOOD SCIENCES&TECH
ABSTRACTS (1969 to November 2008), FOODANDHUMANNUTRITION (1975 to October 2007), AGRIS (1975 to October
2007) (By ERL - Electronic Reference Library): the latter database searches were not updated due to lack of access to them.
#1: (RANDOMIZED-CONTROLLED-TRIAL) or (CONTROLLED-CLINICAL-TRIAL) or RANDOMIZED-CONTROLLED-
TRIALS orRANDOM-ALLOCATIONorDOUBLE-BLIND-METHODor SINGLE-BLIND-METHODor (CLINICAL-TRIAL)
or (CLINICAL-TRIALS) or ((clin* near trial*) in TI) or ((clin* near trial*) in AB) or ((singl* or doubl* or trebl* or tripl*) near (blind*
or mask*)) or ((singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in TI)) or ((singl* or doubl* or trebl* or tripl*) near ((blind*
or mask*) in AB)) or PLACEBOS or (placebo* in TI) or (placebo* in AB) or (random* in TI) or (random* in AB) or RESEARCH-
DESIGN \
#2: ((’POSTPARTUM PERIOD’ or ’MATERNAL-CHILD NURSING’ or ’MATERNAL NUTRITION’ or ’LACTATION’ or
’BREASTFEEDING’ or ’MILK,HUMAN’ or ’POSTNATALCARE’ or ’INFANT,NEWBORN’ or ’INFANT’) inDE) or PUERP* or
MATERN*or LACTA* orBREASTFE* or ’BREASTFE*’ or BREAST-FE* or ’HUMANMILK’ orMILK-HUMANorPOSTNATAL
or POSTPART* or INFANT-NEWBORN* or NEWBORN* or INFANT*
#3: (’Vitamin A’ in DE) or (’Vitamin A Deficiency’ in DE) or (’Carotenoids’ in DE) or caroten* or retinol* or ’vitamin A’
#4: #1 AND #2 AND #3
H I S T O R Y
Protocol first published: Issue 2, 2006
Review first published: Issue 10, 2010
Date Event Description
22 September 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
JM Oliveira-Menegozzo, CE East and P Middleton wrote the review with input from DP Bergamaschi.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• Brazilian Cochrane Center, Brazil.
• Coordenadoria de Aperfeiçoamento do Ensino Superior - CAPES, Brazil.
• Fundação de Amparo à Pesquisa do Estado de SP - FAPESP, Brazil.
• Pró-reitoria de Pesquisa da USP, Brazil.
External sources
• Department of Nutrition for Health and Development, World Health Organization, Switzerland.
Provided funding for the preparation of this review.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Considerable collaborative input from referees, authors and other Cochrane personnel resulted in a focus specifically on postpartum
supplementation, rather than widening to include long-term supplementation during women’s reproductive years.
Criteria for considering studies in this review: we added the potential for including cluster-randomised trials, which were considered
important for the purpose of the review, although none were ultimately included.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Postpartum Period; Infant Mortality; Maternal Mortality; Milk, Human [chemistry]; Randomized Controlled Trials as Topic; Vitamin
A [∗administration & dosage; analysis]; Vitamin A Deficiency [drug therapy]; Vitamins [∗administration & dosage]
MeSH check words
Female; Humans; Infant; Infant, Newborn; Pregnancy
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